Prescription attached:-

đŠē LIPU MED â COMPLETE CLINICAL CASE REVIEW
Prescription Analysis | Clinical Working Diagnosis | MedEx Bangladesh Drug Review | Evidence-Based Management | Doctor’s Dx vs My Dx Comparison
āĻŦāĻžāĻāϞāĻž āϰā§āĻāύāĻŋāϰā§āĻŖāϝāĻŧ: āĻā§āĻŽāϰā§āϰ āύāĻŋāĻā§āϰ āĻ āĻāĻļā§ āĻŦā§āϝāĻĨāĻž (Low Back Pain)āĨ¤ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻžāϰāĻŖ āĻŽā§āϰā§āĻĻāĻŖā§āĻĄ āĻ āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋāϰ āϝāĻžāύā§āϤā§āϰāĻŋāĻ āϏāĻŽāϏā§āϝāĻž (Mechanical Low Back Pain), āϝāĻžāϰ āϏāĻā§āĻā§ āĻā§āĻŽāϰā§āϰ āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋāϤ⧠āĻāĻžāύ āĻŦāĻž āĻāĻŋāĻāĻā§āύāĻŋ (Lumbar Muscle Spasm) āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤ āϤāĻŦā§ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰā§āĻ āĻŦāĻž āĻāĻžāϰāĻŖ āĻāĻāύ⧠āύāĻŋāĻļā§āĻāĻŋāϤ āύāϝāĻŧāĨ¤
Clinical Status: Provisional Working Diagnosis â āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰā§āĻāύāĻŋāϰā§āĻŖāϝāĻŧāĨ¤
Overall Diagnostic Confidence: 0.78/1.00
Prescription: 1
Investigation Report: 0
Additional Clinical Image: 0
Publication Date: Wednesday, 21 October 2026
â Corrected Medicine Identification
āĻāĻĒāύāĻžāϰ āϏāĻāĻļā§āϧāύ āĻ āύā§āϝāĻžāϝāĻŧā§ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ ā§Ē āύāĻŽā§āĻŦāϰ āĻāώā§āϧāĻāĻŋ Sante āĻšāĻŋāϏā§āĻŦā§ āĻ āύā§āϤāϰā§āĻā§āĻā§āϤ āĻāϰāĻž āĻšāϝāĻŧā§āĻā§āĨ¤
MedEx āϝāĻžāĻāĻžāĻ āĻāϰ⧠āĻĒāĻžāĻāϝāĻŧāĻž āϏāĻ āĻŋāĻ āϤāĻĨā§āϝ:
Brand: Sante
Generic: Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C
Form: Effervescent Tablet
Manufacturer: Healthcare Pharmaceuticals Ltd.
Important: Sante-āĻāϰ āĻāĻ formulation-āĻ Vitamin D3 āύā§āĻāĨ¤ āĻāĻāĻŋ āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽ āĻ āĻāĻŋāĻāĻžāĻŽāĻŋāύ C-āĻāϰ combinationāĨ¤
đĸ SECTION 01 | Website-Verified Case Identification / āĻāϝāĻŧā§āĻŦāϏāĻžāĻāĻ āϝāĻžāĻāĻžāĻāĻā§āϤ āĻā§āϏ āĻĒāϰāĻŋāĻāĻŋāϤāĻŋ
Website: raiyyantahsan.com
āĻāϝāĻŧā§āĻŦāϏāĻžāĻāĻā§āϰ Medical Blog āĻ Orthopedics āĻŦāĻŋāĻāĻžāĻ āϝāĻžāĻāĻžāĻ āĻāϰ⧠āύāĻŋāĻā§āϰ āϤāĻĨā§āϝ āĻĒāĻžāĻāϝāĻŧāĻž āĻā§āĻā§āĨ¤
| Parameter / āĻŦāĻŋāώāϝāĻŧ | Verified Information / āϝāĻžāĻāĻžāĻāĻā§āϤ āϤāĻĨā§āϝ |
|---|---|
| Latest Published Global TC | TC (1418) |
| Latest Orthopedics Case | Case No (184) |
| Department Code | 05 |
| Proposed New Global TC | TC (1419) |
| Proposed Orthopedics Case | 185 |
| Department | Orthopedics / āĻ āϰā§āĻĨā§āĻĒā§āĻĄāĻŋāĻā§āϏ |
| Current Case | Low Back Pain |
| Case Status | New proposed publication number |
āϏāϰā§āĻŦāĻļā§āώ āĻĒā§āϰāĻāĻžāĻļāĻŋāϤ Orthopedics Case No (184)-āĻāϰ āĻŦāĻŋāώāϝāĻŧ āĻāĻŋāϞ Suspected Musculoskeletal Chest Wall PaināĨ¤ āύāϤā§āύ āύāĻŋāĻŦāύā§āϧā§āϰ āĻāύā§āϝ āϤāĻžāĻ TC (1419) āĻāĻŦāĻ Orthopedics Case No (185) āĻĒā§āϰāϏā§āϤāĻžāĻŦ āĻāϰāĻž āĻšāϝāĻŧā§āĻā§āĨ¤
Website Verification Confidence: 0.99
Limitation: āύāĻŽā§āĻŦāϰ āĻĻā§āĻāĻŋ āĻāĻāύ⧠āĻĒā§āϰāĻāĻžāĻļ āĻŦāĻž reserve āĻāϰāĻž āĻšāϝāĻŧāύāĻŋāĨ¤ āĻĒāϰāĻŦāϰā§āϤā§āϤ⧠āύāϤā§āύ āĻĒā§āϏā§āĻ āĻĒā§āϰāĻāĻžāĻļāĻŋāϤ āĻšāϞ⧠numbering āĻĒāϰāĻŋāĻŦāϰā§āϤāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
đĸ SECTION 02 | Original Prescription Review / āĻŽā§āϞ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻŦāĻŋāĻļā§āϞā§āώāĻŖ
A. Patient Identification / āϰā§āĻā§āϰ āĻĒāϰāĻŋāĻāϝāĻŧ
| Clinical Parameter | Prescription Finding |
|---|---|
| Patient Name / āϰā§āĻā§āϰ āύāĻžāĻŽ | āĻšāĻžāϤā§āϰ āϞā§āĻāĻž āĻ āϏā§āĻĒāώā§āĻ |
| Age / āĻŦāϝāĻŧāϏ | āύāĻŋāĻļā§āĻāĻŋāϤāĻāĻžāĻŦā§ āĻĒāĻĄāĻŧāĻž āϝāĻžāĻā§āĻā§ āύāĻž |
| Sex / āϞāĻŋāĻā§āĻ | āύāĻŋāĻļā§āĻāĻŋāϤ āύāϝāĻŧ |
| Registration Number | āϏā§āĻĒāώā§āĻ āύāϝāĻŧ |
| Prescription Date | āύāĻŋāĻļā§āĻāĻŋāϤāĻāĻžāĻŦā§ āĻĒāĻĄāĻŧāĻž āϝāĻžāĻā§āĻā§ āύāĻž |
| Doctor’s Specialty | Orthopedics â āϏāĻŽā§āĻāĻžāĻŦā§āϝ |
| C/C â Chief Complaint | Probable LBP |
| O/E â On Examination | āĻāϞā§āϞā§āĻ āύā§āĻ |
| I/H â Illness History | āĻāϞā§āϞā§āĻ āύā§āĻ |
| O/H â Obstetric History | āĻāϞā§āϞā§āĻ āύā§āĻ |
| D/H â Drug History | āĻāϞā§āϞā§āĻ āύā§āĻ |
| M/H â Medical History | āĻāϞā§āϞā§āĻ āύā§āĻ |
| O/S/E â Systemic Examination | āĻāϞā§āϞā§āĻ āύā§āĻ |
| O/G/E â Obstetric/Gynecological Examination | āĻāϞā§āϞā§āĻ āύā§āĻ |
| Dx â Diagnosis | Probable LBP |
| Ix â Investigations | āϏā§āĻĒāώā§āĻ āĻā§āύ⧠āĻĒāϰā§āĻā§āώāĻž āύā§āĻ |
| Plan â Treatment Plan | āĻĒā§āϰāϧāĻžāύāϤ medication-based treatment |
| Advice â āĻĒāϰāĻžāĻŽāϰā§āĻļ | āĻŦāĻŋāϏā§āϤāĻžāϰāĻŋāϤ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āĻĒāĻĄāĻŧāĻž āϝāĻžāĻā§āĻā§ āύāĻž |
Prescription Reading Confidence: 0.76
B. Doctor’s Prescribed Medicines / āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϞāĻŋāĻāĻŋāϤ āĻāώā§āϧ
| No. | Brand | Generic | Prescription Confidence |
|---|---|---|---|
| 1 | Flexi 100 mg | Aceclofenac | 0.92 |
| 2 | Seclo 20 mg | Omeprazole | 0.91 |
| 3 | Relentus | Tizanidine Hydrochloride | 0.83 |
| 4 | Sante â | Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C | 1.00 â user-confirmed brand |
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻāĻā§āĻŦāĻžāϰ⧠āύāĻŋāĻā§āϰ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āϞā§āĻāĻžāĻāĻŋ āĻāώā§āϧ, follow-up instruction āύāĻžāĻāĻŋ āĻ āύā§āϝ āĻā§āύ⧠āύā§āĻâāύāĻŋāĻļā§āĻāĻŋāϤāĻāĻžāĻŦā§ āĻĒāĻĄāĻŧāĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤ āϤāĻžāĻ āϏā§āĻāĻŋāĻā§ āĻĒāĻā§āĻāĻŽ āĻāώā§āϧ āĻšāĻŋāϏā§āĻŦā§ āĻāĻŖāύāĻž āĻāϰāĻž āĻšāĻā§āĻā§ āύāĻžāĨ¤
āĻāĻžāϰāĻāĻŋ āĻŦā§āϰā§āϝāĻžāύā§āĻĄā§āϰ MedEx generic āĻ therapeutic classification āϝāĻžāĻāĻžāĻāĻā§āϤāĨ¤
đĸ SECTION 03 | Chief Complaint (C/C) / āϰā§āĻā§āϰ āĻĒā§āϰāϧāĻžāύ āĻ āĻāĻŋāϝā§āĻ
3.1 Doctor’s Documented Complaint
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻŦāĻžāĻŽ āĻĒāĻžāĻļā§ āϏāĻŽā§āĻāĻŦāϤ LBP āϞā§āĻāĻž āĻšāϝāĻŧā§āĻā§āĨ¤
LBP = Low Back Pain â āĻā§āĻŽāϰā§āϰ āύāĻŋāĻā§āϰ āĻ āĻāĻļā§ āĻŦā§āϝāĻĨāĻžāĨ¤
Definition / āϏāĻāĻā§āĻāĻž
Low Back Pain āĻŦāϞāϤ⧠āϏāĻžāϧāĻžāϰāĻŖāϤ āĻĒāĻŋāĻ ā§āϰ āύāĻŋāĻā§āϰ āĻ āĻāĻļā§, āύāĻŋāĻŽā§āύāϤāĻŽ āĻĒāĻžāĻāĻāϰ āĻāĻŦāĻ āύāĻŋāϤāĻŽā§āĻŦā§āϰ āĻāĻĒāϰā§āϰ āĻāĻžāĻāĻā§āϰ āĻŽāϧā§āϝāĻŦāϰā§āϤ⧠āĻ āĻā§āĻāϞ⧠āĻŦā§āϝāĻĨāĻž āĻŦāĻž āĻ āϏā§āĻŦāϏā§āϤāĻŋāĻā§ āĻŦā§āĻāĻžāϝāĻŧāĨ¤
Possible Symptoms / āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϞāĻā§āώāĻŖ
1. Lumbar Pain â āĻā§āĻŽāϰāĻŦā§āϝāĻĨāĻž: āĻā§āĻŽāϰā§āϰ āύāĻŋāĻā§āϰ āĻ āĻāĻļā§ āĻŦā§āϝāĻĨāĻžāĨ¤
2. Muscle Stiffness â āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋ āĻļāĻā§āϤ āĻšāϝāĻŧā§ āϝāĻžāĻāϝāĻŧāĻž: āĻā§āĻŽāϰ āύāĻĄāĻŧāĻžāĻāĻĄāĻŧāĻžāϝāĻŧ āĻ āϏā§āĻŦāϏā§āϤāĻŋāĨ¤
3. Muscle Spasm â āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋāϤ⧠āĻāĻŋāĻāĻā§āύāĻŋ: āĻā§āĻŽāϰā§āϰ āĻĒā§āĻļāĻŋ āĻ āύāĻŋāĻā§āĻāĻžāĻā§āϤāĻāĻžāĻŦā§ āϏāĻāĻā§āĻāĻŋāϤ āĻšāĻāϝāĻŧāĻžāĨ¤
4. Restricted Movement â āύāĻĄāĻŧāĻžāĻāĻĄāĻŧāĻž āĻāĻŽā§ āϝāĻžāĻāϝāĻŧāĻž: āϏāĻžāĻŽāύ⧠āĻā§āĻāĻāϤ⧠āĻŦāĻž āϏā§āĻāĻž āĻšāϤ⧠āĻ āϏā§āĻŦāĻŋāϧāĻžāĨ¤
5. Radiating Pain â āĻāĻĄāĻŧāĻŋāϝāĻŧā§ āϝāĻžāĻāϝāĻŧāĻž āĻŦā§āϝāĻĨāĻž: āĻā§āύ⧠āĻā§āύ⧠āϰā§āĻā§āϰ āĻā§āĻŽāϰ āĻĨā§āĻā§ āύāĻŋāϤāĻŽā§āĻŦ āĻŦāĻž āĻĒāĻžāϝāĻŧā§āϰ āĻĻāĻŋāĻā§ āĻŦā§āϝāĻĨāĻž āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
Clinical Interpretation: āĻĒā§āϰāĻĨāĻŽ āĻāĻĒāϏāϰā§āĻāĻāĻŋ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ LBP notation-āĻāϰ āϏāĻā§āĻā§ āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖāĨ¤ āĻŦāĻžāĻāĻŋ āĻāĻĒāϏāϰā§āĻāĻā§āϞ⧠āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āύāĻŋāĻļā§āĻāĻŋāϤāĻāĻžāĻŦā§ āύāĻĨāĻŋāĻā§āĻā§āϤ āύāϝāĻŧāĨ¤
Clinical Confidence: 0.82
đĸ SECTION 04 | Patient History Assessment / āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ
4.1 I/H â Illness History / āĻŦāϰā§āϤāĻŽāĻžāύ āĻ āϏā§āϏā§āĻĨāϤāĻžāϰ āĻāϤāĻŋāĻšāĻžāϏ
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻŦā§āϝāĻĨāĻžāϰ āϏā§āĻĨāĻžāϝāĻŧāĻŋāϤā§āĻŦ āĻŦāĻž onset āϏā§āĻĒāώā§āĻ āύāϝāĻŧāĨ¤
āύāĻŋāĻā§āϰ āĻŦāĻŋāώāϝāĻŧāĻā§āϞ⧠āĻāĻŋāĻā§āĻā§āϏ āĻāϰāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
| Clinical Question | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ | Documentation |
|---|---|---|
| Onset | āĻŦā§āϝāĻĨāĻž āĻāĻŦā§ āĻļā§āϰ⧠āĻšāϝāĻŧā§āĻā§? | Unknown |
| Duration | āĻāϤ āĻĻāĻŋāύ āϧāϰ⧠āĻŦā§āϝāĻĨāĻž? | Unknown |
| Location | āĻā§āĻŽāϰā§āϰ āĻ āĻŋāĻ āĻā§āĻĨāĻžāϝāĻŧ āĻŦā§āϝāĻĨāĻž? | Probable lumbar region |
| Radiation | āĻŦā§āϝāĻĨāĻž āĻāĻŋ āĻĒāĻžāϝāĻŧā§ āĻāĻĄāĻŧāĻžāϝāĻŧ? | Unknown |
| Pain Severity | āĻŦā§āϝāĻĨāĻžāϰ āϤā§āĻŦā§āϰāϤāĻž āĻāϤ? | Unknown |
| Morning Stiffness | āϏāĻāĻžāϞ⧠āĻā§āĻŽāϰ āĻļāĻā§āϤ āĻšāϝāĻŧā§ āĻĨāĻžāĻā§? | Unknown |
| Trauma | āĻā§āύ⧠āĻāĻāĻžāϤā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āĻāĻā§? | Unknown |
| Neurological Symptoms | āĻĒāĻžāϝāĻŧā§ āĻ āĻŦāĻļāĻāĻžāĻŦ āĻŦāĻž āĻĻā§āϰā§āĻŦāϞāϤāĻž āĻāĻā§? | Unknown |
4.2 O/H â Obstetric History / āĻĒā§āϰāϏā§āϤāĻŋāϏāĻāĻā§āϰāĻžāύā§āϤ āĻāϤāĻŋāĻšāĻžāϏ
Doctor’s Documentation: Not mentioned â āĻāϞā§āϞā§āĻ āύā§āĻāĨ¤
āϰā§āĻā§ āĻĒā§āϰāĻāύāύāĻā§āώāĻŽ āύāĻžāϰ⧠āĻšāϞ⧠Pregnancy Status â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻāĻā§ āĻāĻŋ āύāĻž â āĻāĻžāύāĻž āĻāϰā§āϰāĻŋāĨ¤ āĻŦāĻŋāĻļā§āώ āĻāϰ⧠NSAID āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻā§āĨ¤
4.3 D/H â Drug History / āĻāώā§āϧ āĻā§āϰāĻšāĻŖā§āϰ āĻĒā§āϰā§āĻŦ āĻāϤāĻŋāĻšāĻžāϏ
Doctor’s Documentation: Not mentioned.
āĻāĻžāύāϤ⧠āĻšāĻŦā§ āĻĒā§āϰā§āĻŦā§ NSAID, corticosteroid, anticoagulant, antihypertensive āĻāĻŋāĻāĻŦāĻž āĻ āύā§āϝ muscle relaxant āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻšāϝāĻŧā§āĻā§ āĻāĻŋ āύāĻžāĨ¤
4.4 M/H â Medical History / āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ
āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ:
- Peptic Ulcer Disease â āĻĒāĻžāĻāϏā§āĻĨāϞ⧠āĻŦāĻž āĻĄā§āĻāĻĄā§āύāĻžāĻŽā§āϰ āĻāϞāϏāĻžāϰāĨ¤
- Chronic Kidney Disease â āĻĻā§āϰā§āĻāϏā§āĻĨāĻžāϝāĻŧā§ āĻāĻŋāĻĄāύāĻŋ āϰā§āĻāĨ¤
- Hypertension â āĻāĻā§āĻ āϰāĻā§āϤāĻāĻžāĻĒāĨ¤
- Diabetes Mellitus â āĻĄāĻžāϝāĻŧāĻžāĻŦā§āĻāĻŋāϏāĨ¤
- Osteoporosis â āĻšāĻžāĻĄāĻŧā§āϰ āĻāύāϤā§āĻŦ āĻāĻŽā§ āϝāĻžāĻāϝāĻŧāĻžāϰ āϰā§āĻāĨ¤
- Previous Spinal Disease â āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻŽā§āϰā§āĻĻāĻŖā§āĻĄā§āϰ āϰā§āĻāĨ¤
āĻāϏāĻŦ āϰā§āĻā§āϰ āĻā§āύā§āĻāĻŋāĻ āĻŦāϰā§āϤāĻŽāĻžāύ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āύāĻŋāĻļā§āĻāĻŋāϤāĻāĻžāĻŦā§ āĻāϞā§āϞā§āĻ āύā§āĻāĨ¤
4.5 Other Relevant History / āĻ āύā§āϝāĻžāύā§āϝ āĻāϤāĻŋāĻšāĻžāϏ
Surgical History: āĻĒā§āϰā§āĻŦā§ āĻŽā§āϰā§āĻĻāĻŖā§āĻĄā§āϰ āĻ āĻĒāĻžāϰā§āĻļāύ āĻšāϝāĻŧā§āĻā§ āĻāĻŋ āύāĻžāĨ¤
Allergy History: āĻŦāĻŋāĻļā§āώ āĻāϰ⧠NSAID allergy āĻāĻā§ āĻāĻŋ āύāĻžāĨ¤
Occupational History: āĻĻā§āϰā§āĻāĻā§āώāĻŖ āĻŦāϏ⧠āĻāĻžāĻ āĻāϰāĻž, āĻāĻžāϰ⧠āĻāĻŋāύāĻŋāϏ āϤā§āϞāĻž āĻŦāĻž repetitive bending-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏāĨ¤
Family History: āĻĒā§āϰāĻžāϏāĻā§āĻāĻŋāĻ rheumatological disease-āĻāϰ āĻĒāĻžāϰāĻŋāĻŦāĻžāϰāĻŋāĻ āĻāϤāĻŋāĻšāĻžāϏāĨ¤
History Assessment Confidence: 0.99 â āĻāĻā§āϞ⧠āĻĒā§āϰāϝāĻŧā§āĻāύā§āϝāĻŧ history items; āϰā§āĻā§āϰ āĻĒā§āϰāĻā§āϤ history āĻĒāĻžāĻāϝāĻŧāĻž āϝāĻžāϝāĻŧāύāĻŋāĨ¤
đĸ SECTION 05 | O/E, O/S/E & O/G/E â Clinical Examination / āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž
5.1 O/E â On Examination
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āύāĻŋāϰā§āĻāϰāϝā§āĻā§āϝ examination findings āύā§āĻāĨ¤
Low Back Pain āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ⧠āĻĒā§āϰāϝāĻŧā§āĻāύā§āϝāĻŧ āĻĒāϰā§āĻā§āώāĻžāĻā§āϞā§:
| Examination | English Finding to Assess | āĻŦāĻžāĻāϞāĻž āĻāĻĻā§āĻĻā§āĻļā§āϝ |
|---|---|---|
| General Examination | Vital signs, fever, general condition | āϏāĻžāϧāĻžāϰāĻŖ āĻļāĻžāϰā§āϰāĻŋāĻ āĻ āĻŦāϏā§āĻĨāĻž |
| Spine Inspection | Posture, deformity, spinal alignment | āĻŽā§āϰā§āĻĻāĻŖā§āĻĄā§āϰ āĻāĻ āύ |
| Lumbar Palpation | Tenderness, paraspinal spasm | āĻāĻžāĻĒ āĻĻāĻŋāϞ⧠āĻŦā§āϝāĻĨāĻž āĻŦāĻž āĻĒā§āĻļāĻŋāϤ⧠āĻāĻžāύ |
| Range of Motion | Flexion, extension, lateral movement | āĻā§āĻŽāϰā§āϰ āύāĻĄāĻŧāĻžāĻāĻĄāĻŧāĻž |
| SLR Test | Straight Leg Raising | āϏā§āύāĻžāϝāĻŧā§āĻŽā§āϞā§āϰ irritation-āĻāϰ āϞāĻā§āώāĻŖ |
| Motor Examination | Lower-limb muscle power | āĻĒāĻžāϝāĻŧā§āϰ āĻļāĻā§āϤāĻŋ |
| Sensory Examination | Dermatomal sensation | āĻĒāĻžāϝāĻŧā§āϰ āĻ āύā§āĻā§āϤāĻŋ |
| Reflex Examination | Knee and ankle reflexes | āϏā§āύāĻžāϝāĻŧā§āϰ reflex |
| Gait Examination | Walking pattern | āĻšāĻžāĻāĻāĻžāϰ āϧāϰāύ |
SLR Positive āĻĨāĻžāĻāϞ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ clinical context-āĻ lumbosacral nerve-root irritation-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āĻŦāĻžāĻĄāĻŧāϤ⧠āĻĒāĻžāϰā§āĨ¤ āϤāĻŦā§ SLR āĻāĻāĻž disc herniation āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰ⧠āύāĻžāĨ¤
5.2 O/S/E â Other/Systemic Examination
āĻĒā§āϰāϝāĻŧā§āĻāύ⧠abdominal, vascular āĻ neurological examination āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
āĻŦāĻžāĻāϞāĻž: āĻā§āĻŽāϰāĻŦā§āϝāĻĨāĻžāϰ āĻāĻžāϰāĻŖ āĻ āύā§āϝ āĻā§āύ⧠āĻ āĻā§āĻ āĻĨā§āĻā§ āĻāϏāĻā§ āĻāĻŋ āύāĻž āĻāĻŦāĻ āϏā§āύāĻžāϝāĻŧā§āϰ āϏāĻŽāϏā§āϝāĻž āĻāĻā§ āĻāĻŋ āύāĻž āĻŽā§āϞā§āϝāĻžāϝāĻŧāύāĨ¤
5.3 O/G/E â Obstetric/Gynecological Examination
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻāϞā§āϞā§āĻ āύā§āĻāĨ¤
āĻĒā§āϰāĻžāϏāĻā§āĻāĻŋāĻ reproductive āĻŦāĻž pelvic symptoms āĻĨāĻžāĻāϞ⧠āĻāϞāĻžāĻĻāĻž gynecological assessment āĻĒā§āϰāϝāĻŧā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Examination Recommendation Confidence: 0.98
đĸ SECTION 06 | Investigations & Diagnostic Reports / āĻĒāϰā§āĻā§āώāĻž-āύāĻŋāϰā§āĻā§āώāĻž āĻ āϰāĻŋāĻĒā§āϰā§āĻ
6.1 Doctor’s Prescribed Investigation
No clearly documented investigation.
āĻāĻŦāĻŋāϤ⧠X-ray, MRI āĻŦāĻž Laboratory Investigation āύāĻŋāĻļā§āĻāĻŋāϤāĻāĻžāĻŦā§ āĻĒāĻĄāĻŧāĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤
6.2 Guideline-Based Recommended Investigations
| Investigation | When Appropriate | āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž |
|---|---|---|
| X-ray Lumbosacral Spine | Suspected fracture or selected bony pathology | āĻšāĻžāĻĄāĻŧ āĻāĻžāĻāĻž āĻŦāĻž āĻāĻ āύāĻāϤ āϏāĻŽāϏā§āϝāĻž āϏāύā§āĻĻā§āĻš āĻšāϞ⧠|
| MRI Lumbosacral Spine | Serious neurological compression, cauda equina, infection, malignancy or specialist-directed assessment | āĻā§āϰā§āϤāϰ āϏā§āύāĻžāϝāĻŧā§ āĻŦāĻž āĻŽā§āϰā§āĻĻāĻŖā§āĻĄā§āϰ āϰā§āĻ āϏāύā§āĻĻā§āĻš āĻšāϞ⧠|
| CBC | Suspected infection or systemic disease | āϏāĻāĻā§āϰāĻŽāĻŖ āĻŦāĻž āϏāĻŋāϏā§āĻā§āĻŽāĻŋāĻ āϰā§āĻā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž |
| ESR/CRP | Selected inflammatory or infectious conditions | āĻĒā§āϰāĻĻāĻžāĻš āĻŦāĻž āϏāĻāĻā§āϰāĻŽāĻŖ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ |
| Serum Creatinine/eGFR | Renal-risk assessment before or during NSAID therapy when indicated | āĻāĻŋāĻĄāύāĻŋāϰ āĻāĻžāϰā§āϝāĻā§āώāĻŽāϤāĻž |
| Serum Calcium | Suspected calcium disorder | āϰāĻā§āϤā§āϰ āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽ |
| 25-OH Vitamin D | Selected patients with suspected deficiency or metabolic bone disease | āĻāĻŋāĻāĻžāĻŽāĻŋāύ D-āĻāϰ āĻāĻžāĻāϤāĻŋ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ |
| DXA Scan | When osteoporosis risk assessment indicates bone-density testing | āĻšāĻžāĻĄāĻŧā§āϰ āĻāύāϤā§āĻŦ āĻĒāϰā§āĻā§āώāĻž |
Important Clinical Point
Sante prescribed â Confirmed Calcium Deficiency.
Sante āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧā§āĻā§ āĻŦāϞ⧠āϰā§āĻā§āϰ calcium deficiency āĻŦāĻž osteoporosis āύāĻŋāĻļā§āĻāĻŋāϤ āύāϝāĻŧāĨ¤
NICE Recommendation
Red flag āĻāĻžāĻĄāĻŧāĻž āϏāĻžāϧāĻžāϰāĻŖ Low Back Pain-āĻ routine imaging āĻĒā§āϰāϝāĻŧā§āĻāύ āĻšāϝāĻŧ āύāĻžāĨ¤ Specialist setting-āĻ imaging āĻĢāϞāĻžāĻĢāϞ āĻāĻŋāĻāĻŋā§āϏāĻž āĻĒāϰāĻŋāĻŦāϰā§āϤāύ āĻāϰāĻŦā§ āĻŦāϞ⧠āĻŽāύ⧠āĻšāϞ⧠āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āĻšāϝāĻŧāĨ¤
Investigation Assessment Confidence: 0.98
đŠ SECTION 07 | PRESCRIBED DRUG ANALYSIS â MEDEX āĻ āύā§āϝāĻžāϝāĻŧā§
đ DRUG 01 â FLEXI 100 mg
Brand Identification Confidence: 0.92
MedEx Pharmacological Verification Confidence: 0.99
1. Generic Name / āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Aceclofenac 100 mg â āĻāϏāĻŋāĻā§āϞā§āĻĢā§āύāĻžāĻāĨ¤
2. Brand Name / āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
Flexi 100 mg
Manufacturer: Square Pharmaceuticals PLC.
3. MedEx Alternative Brand / āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
āĻāĻāĻ generic-āĻāϰ āĻāϝāĻŧā§āĻāĻāĻŋ āĻŦāĻŋāĻāϞā§āĻĒ:
- Acebid 100 mg
- Acedol 100 mg
- Acefenac 100 mg
- Aceclof 100 mg
āĻāϏāĻŦ alternative brand āĻāĻāĻ āϏāĻā§āĻā§ āĻā§āϰāĻšāĻŖā§āϰ āĻāύā§āϝ āύāϝāĻŧāĨ¤
4. MedEx Therapeutic Class / āĻāĻŋāĻāĻŋā§āϏāĻžāĻāϤ āĻļā§āϰā§āĻŖāĻŋ
Drugs for Osteoarthritis; Drugs used for Rheumatoid Arthritis; Non-steroidal Anti-inflammatory Drugs (NSAIDs).
āĻŦāĻžāĻāϞāĻž: āĻ āϏā§āĻĨāĻŋāϏāύā§āϧāĻŋāϰ āĻā§āώāϝāĻŧāĻāύāĻŋāϤ āϰā§āĻ, āϰāĻŋāĻāĻŽāĻžāĻāϝāĻŧā§āĻĄ āĻāϰā§āĻĨā§āϰāĻžāĻāĻāĻŋāϏ āĻāĻŦāĻ āĻŦā§āϝāĻĨāĻž-āĻĒā§āϰāĻĻāĻžāĻšā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāϝāĻŧ āĻŦā§āϝāĻŦāĻšā§āϤ āĻāώā§āϧāĨ¤
5. Pharmacological Class / āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
NSAID â Non-steroidal Anti-inflammatory Drug.
āĻŦāĻžāĻāϞāĻž: āϏā§āĻā§āϰāϝāĻŧā§āĻĄāĻŦāĻŋāĻšā§āύ āĻĒā§āϰāĻĻāĻžāĻšāύāĻžāĻļāĻ āĻ āĻŦā§āϝāĻĨāĻžāύāĻžāĻļāĻāĨ¤
6. Use/Purpose of Drug / āĻāώā§āϧā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
Analgesic and Anti-inflammatory Action.
āĻŦāĻžāĻāϞāĻž: āĻŦā§āϝāĻĨāĻž āĻ āĻĒā§āϰāĻĻāĻžāĻš āĻāĻŽāĻžāύā§āĨ¤
7. Why Doctor Prescribed This Drug / āĻā§āύ āĻāĻŋāĻāĻŋā§āϏāĻ āĻĻāĻŋāϝāĻŧā§āĻā§āύ?
āϏāĻŽā§āĻāĻŦāϤ āϰā§āĻā§āϰ Low Back Pain āĻāĻŽāĻžāύā§āϰ āĻāύā§āϝāĨ¤
Aceclofenac-āĻāϰ approved indications-āĻāϰ āĻŽāϧā§āϝ⧠Lumbago â āĻā§āĻŽāϰāĻŦā§āϝāĻĨāĻž āϰāϝāĻŧā§āĻā§āĨ¤
Case-Specific Confidence: 0.88
8. Side Effects / āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋāϝāĻŧāĻž
Common: Dyspepsia, nausea, abdominal discomfort, dizzinessāĨ¤
Serious: Gastrointestinal bleeding, peptic ulceration, kidney injury, cardiovascular complicationsāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻŦāĻĻāĻšāĻāĻŽ, āĻŦāĻŽāĻŋāĻāĻžāĻŦ, āĻĒā§āĻāĻŦā§āϝāĻĨāĻž, āĻŽāĻžāĻĨāĻž āĻā§āϰāĻž, āĻĒāĻžāĻāϏā§āĻĨāϞā§āϤ⧠āϰāĻā§āϤāĻā§āώāϰāĻŖ, āĻāĻŋāĻĄāύāĻŋāϰ āĻā§āώāϤāĻŋ āĻāĻŦāĻ āĻšā§āĻĻā§âāϰā§āĻāϏāĻāĻā§āϰāĻžāύā§āϤ āĻā§āĻāĻāĻŋāĨ¤
9. MedEx Official Link
10. Unit Price, Strip Price & Other Composition
| Product | MedEx Price |
|---|---|
| Flexi 100 mg | ā§ŗ7.00/tablet |
| Flexi 100 mg â 10 tablets | ā§ŗ70.00 |
| Flexi SR 200 mg | ā§ŗ8.00/tablet |
| Flexi SR 200 mg â 10 tablets | ā§ŗ80.00 |
Other Available Form: Sustained-release 200 mg tabletāĨ¤
Note: Flexi SR 200 mg āĻāĻŦāĻ Flexi 100 mg-āĻāϰ dosing schedule āĻāĻ āύāϝāĻŧāĨ¤
11. Mechanism of Action / āĻāĻžāϰā§āϝāĻĒāĻĻā§āϧāϤāĻŋ
Aceclofenac inhibits cyclooxygenase enzymes and reduces prostaglandin synthesis.
āĻŦāĻžāĻāϞāĻž: Cyclooxygenase enzyme-āĻāϰ āĻāĻžāϰā§āϝāĻā§āϰāĻŽ āĻāĻŽāĻŋāϝāĻŧā§ prostaglandin āĻā§āĻĒāĻžāĻĻāύ āĻāĻŽāĻžāϝāĻŧāĨ¤ āĻĢāϞ⧠āĻŦā§āϝāĻĨāĻž āĻ āĻĒā§āϰāĻĻāĻžāĻš āĻšā§āϰāĻžāϏ āĻĒāĻžāϝāĻŧāĨ¤
12. Drug Indications / āĻā§āύ āĻā§āύ āϰā§āĻā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻšāϝāĻŧ?
Osteoarthritis â āĻ āϏā§āĻĨāĻŋāϏāύā§āϧāĻŋāϰ āĻā§āώāϝāĻŧāĻāύāĻŋāϤ āĻŦāĻžāϤāĨ¤
Rheumatoid Arthritis â āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āĻ āĻā§āĻāĻŽāĻŋāĻāύ āĻŦāĻžāϤāĨ¤
Ankylosing Spondylitis â āĻŽā§āϰā§āĻĻāĻŖā§āĻĄā§āϰ āĻĻā§āϰā§āĻāϏā§āĻĨāĻžāϝāĻŧā§ āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āϰā§āĻāĨ¤
Lumbago â āĻā§āĻŽāϰāĻŦā§āϝāĻĨāĻžāĨ¤
Dental Pain â āĻĻāĻžāĻāϤā§āϰ āĻŦā§āϝāĻĨāĻžāĨ¤
Traumatic Pain â āĻāĻāĻžāϤāĻāύāĻŋāϤ āĻŦā§āϝāĻĨāĻžāĨ¤
13. Drug Interaction + Contraindications
Interactions: Warfarin, other anticoagulants, methotrexate, lithium, diuretics, ACE inhibitors/ARBs āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ NSAIDsāĨ¤
Contraindications: Aceclofenac hypersensitivity, aspirin/NSAID-induced asthma-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻāĻŦāĻ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ GI bleeding āĻŦāĻž āĻā§āϰā§āϤāϰ āĻ āĻā§āĻ-āĻ āĻāĻžāϰā§āϝāĻāĻžāϰāĻŋāϤāĻžāϰ āĻ āĻŦāϏā§āĻĨāĻžāϝāĻŧ āĻŦā§āϝāĻŦāĻšāĻžāϰ āύāĻŋāώāĻŋāĻĻā§āϧ āĻŦāĻž āĻ āύā§āĻĒāϝā§āĻā§āϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
14. Precautions & Warnings
Peptic ulcer, chronic kidney disease, hypertension, heart failure, dehydration āĻ elderly patients-āĻ āĻŦāĻŋāĻļā§āώ āϏāϤāϰā§āĻāϤāĻžāĨ¤
15. Dosage & Administration
MedEx Adult Reference Dose: 100 mg twice daily.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰāĻžāĻĒā§āϤāĻŦāϝāĻŧāϏā§āĻāĻĻā§āϰ āĻāύā§āϝ āϰā§āĻĢāĻžāϰā§āύā§āϏ āĻŽāĻžāϤā§āϰāĻž āĻĻāĻŋāύ⧠āĻĻā§āĻāĻŦāĻžāϰ ā§§ā§Ļā§Ļ āĻŽāĻŋ.āĻā§āϰāĻž.āĨ¤
āĻāĻāĻŋ āĻāĻ āϰā§āĻā§āϰ āĻĒā§āϰāĻā§āϤ prescribed frequency āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻā§ āύāĻžāĨ¤ āϏā§āĻŦāϞā§āĻĒāϤāĻŽ āϏāĻŽāϝāĻŧā§ āϏāϰā§āĻŦāύāĻŋāĻŽā§āύ āĻāĻžāϰā§āϝāĻāϰ dose āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
16. Pregnancy & Lactation
Pregnancy-āϤ⧠aceclofenac āϏāĻžāϧāĻžāϰāĻŖāϤ āĻāĻĄāĻŧāĻžāύ⧠āĻāĻāĻŋāϤ, āĻŦāĻŋāĻļā§āώāϤ āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻžāϰ ⧍ā§Ļ āϏāĻĒā§āϤāĻžāĻšā§āϰ āĻĒāϰ āĻāĻŦāĻ āϤā§āϤā§āϝāĻŧ trimester-āĻāĨ¤
Breastfeeding-āĻāϰ āϏāĻŽāϝāĻŧ āĻŦāĻŋāĻāϞā§āĻĒ āĻāώā§āϧ āĻ riskâbenefit āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Clinical Confidence: 0.99 â verified drug properties.
đ DRUG 02 â SECLO 20 mg
Brand Identification Confidence: 0.91
MedEx Verification Confidence: 0.99
1. Generic Name
Omeprazole 20 mg â āĻāĻŽāĻŋāĻĒā§āϰāĻžāĻāϞāĨ¤
2. Brand Name
Seclo 20 mg EC Capsule
Manufacturer: Square Pharmaceuticals PLC.
3. MedEx Alternative Brand
āĻāĻāĻ generic-āĻāϰ āĻāĻĻāĻžāĻšāϰāĻŖ:
Seclogen, Losectil āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ omeprazole preparationsāĨ¤
4. MedEx Therapeutic Class
Proton Pump Inhibitor (PPI).
āĻŦāĻžāĻāϞāĻž: āĻĒāĻžāĻāϏā§āĻĨāϞā§āϰ āĻ ā§āϝāĻžāϏāĻŋāĻĄ āύāĻŋāĻāϏāϰāĻŖ āĻāĻŽāĻžāύā§āϰ āĻāώā§āϧāĨ¤
5. Pharmacological Class
Gastric Hâē/Kâē-ATPase Inhibitor.
āĻŦāĻžāĻāϞāĻž: āĻĒāĻžāĻāϏā§āĻĨāϞā§āϰ proton pump āĻŦāύā§āϧ āĻāϰ⧠āĻ ā§āϝāĻžāϏāĻŋāĻĄ āĻāĻŽāĻžāϝāĻŧāĨ¤
6. Use/Purpose of Drug
Acid Suppression and Gastroprotection.
āĻŦāĻžāĻāϞāĻž: āĻĒāĻžāĻāϏā§āĻĨāϞā§āϰ āĻ ā§āϝāĻžāϏāĻŋāĻĄ āĻāĻŽāĻžāύ⧠āĻāĻŦāĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠NSAID-associated ulcer āĻĒā§āϰāϤāĻŋāϰā§āϧāĨ¤
7. Why Doctor Prescribed This Drug
āϏāĻŽā§āĻāĻŦāϤ Flexi (Aceclofenac) āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āϏāĻā§āĻā§ GI protection-āĻāϰ āĻāύā§āϝāĨ¤
āϤāĻŦā§ āϰā§āĻā§āϰ āĻāĻā§ āĻĨā§āĻā§ āĻā§āϝāĻžāϏā§āĻā§āϰāĻŋāĻ āĻāϞāϏāĻžāϰ āĻāĻā§âāĻāĻŽāύ āϤāĻĨā§āϝ āĻĒāĻžāĻāϝāĻŧāĻž āϝāĻžāϝāĻŧāύāĻŋāĨ¤
Case-Specific Confidence: 0.86
8. Side Effects
Headache, nausea, diarrhea, abdominal pain āĻ constipationāĨ¤
āĻĻā§āϰā§āĻāĻŽā§āϝāĻŧāĻžāĻĻāĻŋ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻā§āώā§āϤā§āϰ⧠hypomagnesemia, vitamin B12 deficiency āĻāĻŦāĻ āĻāĻŋāĻā§ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻā§āĻāĻāĻŋ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āĻšāϝāĻŧāĨ¤
9. MedEx Official Link
10. Unit Price, Strip Price & Other Composition
| Product | Price |
|---|---|
| Seclo 20 mg | ā§ŗ6.00/capsule |
| Seclo 20 mg â 10 capsules | ā§ŗ60.00 |
| Seclo 40 mg | ā§ŗ9.00/capsule |
| Seclo 40 mg/vial | ā§ŗ95.00 |
| Seclo MUPS 20 mg | ā§ŗ7.00/tablet |
11. Mechanism of Action
Omeprazole irreversibly inhibits the Hâē/Kâē-ATPase proton pump of gastric parietal cells.
āĻŦāĻžāĻāϞāĻž: āĻĒāĻžāĻāϏā§āĻĨāϞā§āϰ parietal cell-āĻāϰ proton pump āĻŦāύā§āϧ āĻāϰ⧠gastric acid secretion āĻāĻŽāĻžāϝāĻŧāĨ¤
12. Drug Indications
Peptic Ulcer Disease â āĻĒāĻžāĻāϏā§āĻĨāϞ⧠āĻŦāĻž āĻĄā§āĻāĻĄā§āύāĻžāĻŽā§āϰ āĻāϞāϏāĻžāϰāĨ¤
GERD â āĻĒāĻžāĻāϏā§āĻĨāϞā§āϰ āĻ ā§āϝāĻžāϏāĻŋāĻĄ āĻāĻžāĻĻā§āϝāύāĻžāϞāĻŋāϤ⧠āĻāĻ ā§ āĻāϏāĻžāĨ¤
NSAID-associated Ulcer â NSAID-āĻāϰ āĻāĻžāϰāĻŖā§ āĻāϞāϏāĻžāϰāĨ¤
Acid-related Dyspepsia â āĻ ā§āϝāĻžāϏāĻŋāĻĄāĻāύāĻŋāϤ āĻŦāĻĻāĻšāĻāĻŽāĨ¤
H. pylori Eradication Regimen â āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ antibiotic regimen-āĻāϰ āĻ āĻāĻļāĨ¤
ZollingerâEllison Syndrome â āĻ āϤāĻŋāϰāĻŋāĻā§āϤ gastric acid secretion-āĻāϰ āĻŦāĻŋāϰāϞ āϰā§āĻāĨ¤
13. Drug Interaction + Contraindications
Interactions: Clopidogrel, warfarin, phenytoin, high-dose methotrexate āĻāĻŦāĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ antiretroviral āĻŦāĻž antifungal medicineāĨ¤
Contraindications: Omeprazole hypersensitivity āĻāĻŦāĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ contraindicated combinationsāĨ¤
14. Precautions & Warnings
āĻĻā§āϰā§āĻāĻŽā§āϝāĻŧāĻžāĻĻāĻŋ PPI therapy āύāĻŋāϝāĻŧāĻŽāĻŋāϤ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤ āĻĒā§āϰāϝāĻŧā§āĻāύ āĻāĻžāĻĄāĻŧāĻž āĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻāĻāĻžāϞ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻ āĻŋāĻ āύāϝāĻŧāĨ¤
15. Dosage & Administration
MedEx Reference: 20 mg once daily for several acid-related indicationsāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻŦāĻŋāĻāĻŋāύā§āύ acid-related condition-āĻ āϏāĻžāϧāĻžāϰāĻŖāϤ āĻĻāĻŋāύ⧠āĻāĻāĻŦāĻžāϰ ⧍ā§Ļ āĻŽāĻŋ.āĻā§āϰāĻž. āĻŦā§āϝāĻŦāĻšā§āϤ āĻšāϝāĻŧāĨ¤
āĻĒā§āϰāĻā§āϤ indication āĻ āύā§āϝāĻžāϝāĻŧā§ dose āĻ duration āĻāĻŋāύā§āύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
16. Pregnancy & Lactation
āĻĒā§āϰāϝāĻŧā§āĻāύ āĻšāϞ⧠āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻžāϝāĻŧ omeprazole āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āϝāĻžāϝāĻŧāĨ¤ Breastfeeding-āĻāϰ āĻā§āώā§āϤā§āϰā§āĻ āĻŦāϰā§āϤāĻŽāĻžāύ clinical evidence āĻāĻŦāĻ maternal indication āĻ āύā§āϝāĻžāϝāĻŧā§ riskâbenefit āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Clinical Confidence: 0.99
đ DRUG 03 â RELENTUS 2 mg
Brand Identification Confidence: 0.83
MedEx Verification Confidence: 0.99
1. Generic Name
Tizanidine Hydrochloride â āĻāĻŋāĻāĻžāύāĻŋāĻĄāĻŋāύ āĻšāĻžāĻāĻĄā§āϰā§āĻā§āϞā§āϰāĻžāĻāĻĄāĨ¤
2. Brand Name
Relentus 2 mg
Manufacturer: Beximco Pharmaceuticals Ltd.
3. MedEx Alternative Brand
- Tizadin 2 mg
- Tizalex 2 mg
- Tizalud 2 mg
- Tizan 2 mg
- Sirdalud 2 mg
4. MedEx Therapeutic Class
Centrally Acting Skeletal Muscle Relaxants.
āĻŦāĻžāĻāϞāĻž: āĻā§āύā§āĻĻā§āϰā§āϝāĻŧ āϏā§āύāĻžāϝāĻŧā§āϤāύā§āϤā§āϰ⧠āĻāĻžāĻ āĻāϰ⧠āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋ āĻļāĻŋāĻĨāĻŋāϞāĻāĻžāϰ⧠āĻāώā§āϧāĨ¤
5. Pharmacological Class
Alpha-2 Adrenergic Receptor Agonist.
6. Use/Purpose of Drug
Reduction of Painful Muscle Spasm and Spasticity.
āĻŦāĻžāĻāϞāĻž: āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋāϰ āĻŦā§āϝāĻĨāĻžāϝā§āĻā§āϤ āĻāĻžāύ āĻŦāĻž āĻāĻŋāĻāĻā§āύāĻŋ āĻāĻŽāĻžāύā§āĨ¤
7. Why Doctor Prescribed This Drug
āϏāĻŽā§āĻāĻŦāϤ āĻā§āĻŽāϰā§āϰ āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋāϰ spasm āĻāĻŽāĻžāύā§āϰ āĻāύā§āϝ āĻāĻŋāĻāĻŋā§āϏāĻ āĻĻāĻŋāϝāĻŧā§āĻā§āύāĨ¤
āϤāĻŦā§ āϰā§āĻā§āϰ examination-āĻ spasm āĻĒāĻžāĻāϝāĻŧāĻž āĻā§āĻā§âāĻāĻŽāύ āĻĒā§āϰāĻŽāĻžāĻŖ āύā§āĻāĨ¤
Case-Specific Confidence: 0.74
8. Side Effects
Somnolence â āĻā§āĻŽāĻā§āĻŽ āĻāĻžāĻŦāĨ¤
Dizziness â āĻŽāĻžāĻĨāĻž āĻā§āϰāĻžāĨ¤
Dry Mouth â āĻŽā§āĻ āĻļā§āĻāĻŋāϝāĻŧā§ āϝāĻžāĻāϝāĻŧāĻžāĨ¤
Hypotension â āϰāĻā§āϤāĻāĻžāĻĒ āĻāĻŽā§ āϝāĻžāĻāϝāĻŧāĻžāĨ¤
Bradycardia â āĻšā§āĻĻā§âāϏā§āĻĒāύā§āĻĻāύ āϧā§āϰ āĻšāϝāĻŧā§ āϝāĻžāĻāϝāĻŧāĻžāĨ¤
Liver Enzyme Elevation â āϞāĻŋāĻāĻžāϰā§āϰ āĻāύāĻāĻžāĻāĻŽ āĻŦā§āĻĄāĻŧā§ āϝāĻžāĻāϝāĻŧāĻžāĨ¤
9. MedEx Official Link
10. Unit Price, Strip Price & Other Strengths
| Product | Price |
|---|---|
| Relentus 2 mg | ā§ŗ8.00/tablet |
| Relentus 2 mg â 10 tablets | ā§ŗ80.00 |
| Tizadin 2 mg | ā§ŗ5.04/tablet |
| Tizalex 2 mg | ā§ŗ5.00/tablet |
| Tizalud 2 mg | ā§ŗ5.02/tablet |
Relentus āĻŦā§āϰā§āϝāĻžāύā§āĻĄā§āϰ āĻ āύā§āϝ strength MedEx-āĻāϰ āĻāϞā§āϞāĻŋāĻāĻŋāϤ profile-āĻ āϝāĻžāĻāĻžāĻ āĻāϰāĻž āϝāĻžāϝāĻŧāύāĻŋāĨ¤
11. Mechanism of Action
Tizanidine stimulates presynaptic alpha-2 adrenergic receptors in the spinal cord and reduces excitatory neurotransmitter release.
āĻŦāĻžāĻāϞāĻž: āĻŽā§āϰā§āϰāĻā§āĻā§āϰ alpha-2 receptor āϏāĻā§āϰāĻŋāϝāĻŧ āĻāϰ⧠excitatory neurotransmitter āύāĻŋāĻāϏāϰāĻŖ āĻāĻŽāĻžāϝāĻŧāĨ¤ āĻĢāϞ⧠muscle tone āĻ spasm āĻāĻŽāϤ⧠āĻĒāĻžāϰā§āĨ¤
12. Drug Indications
Painful Muscle Spasm â āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋāϰ āĻŦā§āϝāĻĨāĻžāϝā§āĻā§āϤ āĻāĻŋāĻāĻā§āύāĻŋāĨ¤
Cervical/Lumbar Syndromes â āĻāĻžāĻĄāĻŧ āĻ āĻā§āĻŽāϰā§āϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ musculoskeletal syndromesāĨ¤
Spasticity Associated with Multiple Sclerosis â MS-āĻāύāĻŋāϤ āĻĒā§āĻļāĻŋāϰ āĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻļāĻā§āϤ āĻšāϝāĻŧā§ āĻĨāĻžāĻāĻžāĨ¤
Spasticity in Selected Neurological Disorders â āĻāĻŋāĻā§ āϏā§āύāĻžāϝāĻŧāĻŦāĻŋāĻ āϰā§āĻā§ spasticityāĨ¤
13. Drug Interaction + Contraindications
Major Contraindicated Drug Combinations:
Ciprofloxacin āĻāĻŦāĻ fluvoxamineāĨ¤
Other Interactions: Alcohol, sedatives, antihypertensives āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ CNS depressantsāĨ¤
Contraindications: Severe hepatic impairment, hypersensitivity āĻāĻŦāĻ contraindicated CYP1A2 inhibitor combinationsāĨ¤
14. Precautions & Warnings
Sedation, hypotension, falls āĻāĻŦāĻ liver injury-āĻāϰ āĻā§āĻāĻāĻŋ āϏāĻŽā§āĻĒāϰā§āĻā§ āϏāϤāϰā§āĻ āĻĨāĻžāĻāϤ⧠āĻšāĻŦā§āĨ¤
āĻāώā§āϧ āϏā§āĻŦāύā§āϰ āĻĒāϰ⧠āĻŽāĻžāĻĨāĻž āĻā§āϰāĻž āĻŦāĻž āĻā§āĻŽāĻā§āĻŽ āĻāĻžāĻŦ āĻšāϞ⧠āĻāĻžāĻĄāĻŧāĻŋ āĻāĻžāϞāĻžāύ⧠āĻŦāĻž āĻā§āĻāĻāĻŋāĻĒā§āϰā§āĻŖ āϝāύā§āϤā§āϰ āĻĒāϰāĻŋāĻāĻžāϞāύāĻž āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
15. Dosage & Administration
MedEx Reference Dose: Painful muscle spasm-āĻāϰ āĻāύā§āϝ 2â4 mg, āϏāĻžāϧāĻžāϰāĻŖāϤ āĻĻāĻŋāύ⧠āϤāĻŋāύāĻŦāĻžāϰ āĻĒāϰā§āϝāύā§āϤ; treatment individualizedāĨ¤
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āĻ āĻŦāϏā§āĻĨāĻž āĻ āύā§āϝāĻžāϝāĻŧā§ āĻāĻŽ āĻŽāĻžāϤā§āϰāĻžāϝāĻŧ āĻļā§āϰ⧠āĻāϰ⧠dose āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāĻž āĻšāϝāĻŧāĨ¤
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻšāĻžāϤā§āϰ āϞā§āĻāĻž āĻĨā§āĻā§ āϰā§āĻā§āϰ āĻĒā§āϰāĻā§āϤ dose/frequency āύāĻŋāĻļā§āĻāĻŋāϤ āύāϝāĻŧāĨ¤
16. Pregnancy & Lactation
Pregnancy āĻ breastfeeding-āĻāϰ āĻā§āώā§āϤā§āϰ⧠āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻžāϰ āϤāĻĨā§āϝ āϏā§āĻŽāĻŋāϤāĨ¤ āϏā§āĻĒāώā§āĻ āĻĒā§āϰāϝāĻŧā§āĻāύ āĻāĻžāĻĄāĻŧāĻž āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāĻĄāĻŧāĻžāύ⧠āĻāĻāĻŋāϤāĨ¤
Guideline Caution: WHO 2023 guideline āĻ āύā§āϝāĻžāϝāĻŧā§ chronic primary low back pain-āĻ skeletal muscle relaxants routine treatment āĻšāĻŋāϏā§āĻŦā§ āϏā§āĻĒāĻžāϰāĻŋāĻļāĻā§āϤ āύāϝāĻŧāĨ¤
đ DRUG 04 â SANTE â (CORRECTED)
SANTE â Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C
Brand Identification Confidence: 1.00 â āĻāĻĒāύāĻžāϰ āϏāĻāĻļā§āϧāύ āĻ āύā§āϝāĻžāϝāĻŧā§āĨ¤
MedEx Pharmacological Verification Confidence: 0.99
1. Generic Name / āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C
āĻŦāĻžāĻāϞāĻž:
āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽ āϞā§āϝāĻžāĻāĻā§āĻ āĻā§āϞā§āĻā§āύā§āĻ + āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽ āĻāĻžāϰā§āĻŦā§āύā§āĻ + āĻāĻŋāĻāĻžāĻŽāĻŋāύ āϏāĻŋāĨ¤
Composition / āĻāĻĒāĻžāĻĻāĻžāύ
āĻĒā§āϰāϤāĻŋ effervescent tablet-āĻ āϰāϝāĻŧā§āĻā§:
| Ingredient | Quantity | āĻŦāĻžāĻāϞāĻž |
|---|---|---|
| Calcium Lactate Gluconate | 1000 mg | āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽā§āϰ āĻāĻāĻāĻŋ āϞāĻŦāĻŖ |
| Calcium Carbonate | 327 mg | āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽā§āϰ āĻāϰā§āĻāĻāĻŋ āϞāĻŦāĻŖ |
| Vitamin C (Ascorbic Acid) | 500 mg | āĻāĻŋāĻāĻžāĻŽāĻŋāύ āϏāĻŋ |
Important: 1000 mg āĻ 327 mg āĻšāϞ⧠āϏāĻāĻļā§āϞāĻŋāώā§āĻ calcium salt-āĻāϰ āĻĒāϰāĻŋāĻŽāĻžāĻŖ; āĻāĻā§āϞā§āĻā§ āϏāϰāĻžāϏāϰāĻŋ 1327 mg elemental calcium āĻšāĻŋāϏā§āĻŦā§ āĻāĻŖāύāĻž āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Vitamin D3: Not included â āύā§āĻāĨ¤
2. Brand Name / āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
Sante Effervescent Tablet
Manufacturer: Healthcare Pharmaceuticals Ltd., Bangladesh.
3. MedEx Alternative Brand / āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
āĻāĻāĻ generic combination-āĻāϰ āĻāϝāĻŧā§āĻāĻāĻŋ MedEx-listed alternative:
| Alternative Brand | Company | Unit Price |
|---|---|---|
| Calbo-C | Square Pharmaceuticals | ā§ŗ13.00 |
| Cavic-C | Incepta Pharmaceuticals | ā§ŗ13.00 |
| Calfix C | OSL Pharma | ā§ŗ10.00 |
| Ostogen C | Opsonin Pharma | ā§ŗ12.00 |
| Calcefer | Renata | ā§ŗ10.00 |
| Acical-C | ACI | ā§ŗ15.00 |
āĻāĻāĻ active ingredient combination āĻ equivalent formulation āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰ⧠āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āĻā§ āύāĻŋāϤ⧠āĻšāĻŦā§āĨ¤
4. MedEx Therapeutic Class / āĻāĻŋāĻāĻŋā§āϏāĻžāĻāϤ āĻļā§āϰā§āĻŖāĻŋ
Specific Mineral & Vitamin Combined Preparations.
āĻŦāĻžāĻāϞāĻž: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāύāĻŋāĻ āĻ āĻāĻŋāĻāĻžāĻŽāĻŋāύā§āϰ āϏāĻŽāύā§āĻŦāĻŋāϤ āϏāĻŽā§āĻĒā§āϰāĻāĨ¤
5. Pharmacological Class / āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Calcium Supplement + Water-Soluble Vitamin Supplement.
āĻŦāĻžāĻāϞāĻž: āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽ āĻ āĻĒāĻžāύāĻŋāϤ⧠āĻĻā§āϰāĻŦāĻŖā§āϝāĻŧ āĻāĻŋāĻāĻžāĻŽāĻŋāύā§āϰ āϏāĻŽā§āĻĒā§āϰāĻāĨ¤
6. Use/Purpose of Drug / āĻāώā§āϧā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
Sante-āĻāϰ āĻĒā§āϰāϧāĻžāύ āĻāĻĻā§āĻĻā§āĻļā§āϝ:
Calcium Supplementation â āĻļāϰā§āϰ⧠āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽā§āϰ āĻāĻžāĻāϤāĻŋ āĻĒā§āϰāĻŖāĨ¤
Vitamin C Supplementation â āĻāĻŋāĻāĻžāĻŽāĻŋāύ C-āĻāϰ āĻāĻžāĻāϤāĻŋ āĻĒā§āϰāĻŖāĨ¤
Support of Bone Mineral Metabolism â āĻšāĻžāĻĄāĻŧā§āϰ āĻāύāĻŋāĻā§āϰ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻŦāĻŋāĻĒāĻžāĻā§ āϏāĻšāĻžāϝāĻŧāϤāĻžāĨ¤
Correction of Nutritional Deficiency â āĻĒā§āώā§āĻāĻŋāĻāϤ āĻāĻžāĻāϤāĻŋāϰ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
āĻāĻāĻŋ āϏāϰāĻžāϏāϰāĻŋ āĻŦā§āϝāĻĨāĻžāύāĻžāĻļāĻ āĻāώā§āϧ āύāϝāĻŧāĨ¤
7. Why Doctor Prescribed Sante in This Patient / āĻāĻ āϰā§āĻā§āĻā§ āĻā§āύ Sante āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧā§āĻā§?
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠LBP-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāϞā§āϞā§āĻ, analgesic āĻāĻŦāĻ muscle relaxant-āĻāϰ āϏāĻā§āĻā§ Sante āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧā§āĻā§āĨ¤
āĻāĻāĻžāύ⧠āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻĻā§āĻĻā§āĻļā§āϝ āĻšāϤ⧠āĻĒāĻžāϰā§:
A. Suspected Calcium Insufficiency â āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽā§āϰ āĻ āĻĒāϰā§āϝāĻžāĻĒā§āϤāϤāĻž āϏāύā§āĻĻā§āĻšāĨ¤
āϰā§āĻā§āϰ āĻāĻžāĻĻā§āϝāĻžāĻā§āϝāĻžāϏ āĻŦāĻž āĻ āύā§āϝāĻžāύā§āϝ clinical āϤāĻĨā§āϝā§āϰ āĻāĻŋāϤā§āϤāĻŋāϤ⧠āĻāĻŋāĻāĻŋā§āϏāĻ calcium supplementation āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰ⧠āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āύāĨ¤
B. Nutritional Supplementation â āĻĒā§āώā§āĻāĻŋāĻāϤ āϏāĻšāĻžāϝāĻŧāϤāĻžāĨ¤
āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽ āĻ āĻāĻŋāĻāĻžāĻŽāĻŋāύ C-āĻāϰ āĻāĻžāĻšāĻŋāĻĻāĻž āĻĒā§āϰāĻŖā§āϰ āĻāύā§āϝāĨ¤
C. Supportive Bone Health Management â āĻšāĻžāĻĄāĻŧā§āϰ āϏā§āĻŦāĻžāϏā§āĻĨā§āϝ āϰāĻā§āώāĻžāϝāĻŧ āϏāĻšāĻžāϝāĻŧāĻ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ metabolic bone disorder āĻĨāĻžāĻāϞ⧠supplementation āĻĒā§āϰāĻžāϏāĻā§āĻāĻŋāĻ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Critical Clinical Interpretation
Sante prescribing does not establish a diagnosis of osteoporosis, osteomalacia or calcium deficiency.
āĻŦāĻžāĻāϞāĻž: āĻļā§āϧ⧠Sante āĻĻā§āĻāϝāĻŧāĻžāϰ āĻāĻžāϰāĻŖā§ āϰā§āĻā§āϰ osteoporosis, osteomalacia āĻŦāĻž calcium deficiency āĻāĻā§âāĻāĻŽāύ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āύā§āĻāϝāĻŧāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Sante is not an evidence-based primary analgesic treatment for nonspecific low back pain.
āĻŦāĻžāĻāϞāĻž: āϏāĻžāϧāĻžāϰāĻŖ āĻā§āĻŽāϰāĻŦā§āϝāĻĨāĻžāϰ āĻĒā§āϰāϧāĻžāύ āĻŦā§āϝāĻĨāĻžāύāĻžāĻļāĻ āĻāĻŋāĻāĻŋā§āϏāĻž āĻšāĻŋāϏā§āĻŦā§ Sante āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻžāϰ āϏā§āϏā§āĻĒāώā§āĻ āύāĻŋāϰā§āĻĻā§āĻļāĻŋāĻāĻž āύā§āĻāĨ¤
Patient-Specific Rationale Confidence: 0.58 â supplementation-āĻāϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ āϏāĻŽā§āĻāĻžāĻŦā§āϝ, āĻāĻŋāύā§āϤ⧠āϰā§āĻā§āϰ calcium deficiency āĻŦāĻž osteoporosis-āĻāϰ āĻĒā§āϰāĻŽāĻžāĻŖ āύā§āĻāĨ¤
8. Side Effects / āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋāϝāĻŧāĻž
Common/Occasional:
Abdominal Bloating â āĻĒā§āĻ āĻĢāĻžāĻāĻĒāĻžāĨ¤
Diarrhea â āĻĒāĻžāϤāϞāĻž āĻĒāĻžāϝāĻŧāĻāĻžāύāĻžāĨ¤
Gastrointestinal Discomfort â āĻĒā§āĻā§ āĻ āϏā§āĻŦāϏā§āϤāĻŋāĨ¤
Important Risks:
Hypercalcemia â āϰāĻā§āϤ⧠āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽ āĻŦā§āĻĄāĻŧā§ āϝāĻžāĻāϝāĻŧāĻžāĨ¤
Hypercalciuria â āĻĒā§āϰāϏā§āϰāĻžāĻŦā§ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽ āĻŦā§āϰ āĻšāĻāϝāĻŧāĻžāĨ¤
Renal Calculi â āĻāĻŋāĻĄāύāĻŋāϤ⧠āĻĒāĻžāĻĨāϰāĨ¤
āĻĻā§āϰā§āĻāĻĻāĻŋāύ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽ āĻā§āϰāĻšāĻŖ āĻāϰāϞ⧠āĻĒā§āϰā§āĻŦāĻĒā§āϰāĻŦāĻŖāϤāĻžāϏāĻŽā§āĻĒāύā§āύ āϰā§āĻā§āϰ āĻāϏāĻŦ āĻā§āĻāĻāĻŋ āĻŦāĻžāĻĄāĻŧāϤ⧠āĻĒāĻžāϰā§āĨ¤
9. MedEx Official Link
Sante Effervescent Tablet â MedEx Official Drug Profile
10. Unit Price, Strip Price & Available Composition
| Product | Price |
|---|---|
| Sante Effervescent Tablet â 1 tablet | ā§ŗ15.00 |
| Sante â 10 tablets | ā§ŗ150.00 |
| Pack | 1 Ã 10 effervescent tablets |
| Manufacturer | Healthcare Pharmaceuticals Ltd. |
Note: MedEx-āĻāϰ āϤāĻžāϞāĻŋāĻāĻžāϝāĻŧ ā§ŗ150.00-āĻā§ Strip Price āĻšāĻŋāϏā§āĻŦā§ āĻĻā§āĻāĻžāύ⧠āĻšāϞā§āĻ āĻāĻāĻŋ effervescent tablet-āĻāϰ ā§§ā§ĻāĻāĻŋāϰ āĻĒā§āϝāĻžāĻ, āϏāĻžāϧāĻžāϰāĻŖ tablet blister strip āύāϝāĻŧāĨ¤
Available as Other Composition
Sante-āĻāϰ āĻ āύā§āϝ strength āĻŦāĻž Vitamin D-containing Sante formulation āĻāĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ MedEx profile-āĻ āϤāĻžāϞāĻŋāĻāĻžāĻā§āĻā§āϤ āύā§āĻāĨ¤
āϤāĻŦā§ āĻāĻāĻ calcium salt-āĻāϰ āϏāĻā§āĻā§ Vitamin D3 āϝā§āĻā§āϤ āĻ āύā§āϝ āĻŦā§āϰā§āϝāĻžāύā§āĻĄā§āϰ combination āĻĒāĻžāĻāϝāĻŧāĻž āϝāĻžāϝāĻŧāĨ¤ āĻāĻā§āϞ⧠Sante-āĻāϰ āϏāϰāĻžāϏāϰāĻŋ equivalent āύāϝāĻŧāĨ¤
11. Mechanism of Action / āĻāώā§āϧā§āϰ āĻāĻžāϰā§āϝāĻĒāĻĻā§āϧāϤāĻŋ
A. Calcium Lactate Gluconate
āĻāĻāĻŋ āĻļāϰā§āϰ⧠calcium āϏāϰāĻŦāϰāĻžāĻš āĻāϰā§āĨ¤
Calcium normal nerve conduction, muscle contraction, cardiac function āĻāĻŦāĻ bone mineralization-āĻāϰ āĻāύā§āϝ āĻĒā§āϰāϝāĻŧā§āĻāύā§āϝāĻŧāĨ¤
āĻŦāĻžāĻāϞāĻž: āϏā§āύāĻžāϝāĻŧā§, āĻĒā§āĻļāĻŋ, āĻšā§āĻĻā§âāϝāύā§āϤā§āϰ āĻ āĻšāĻžāĻĄāĻŧā§āϰ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻāĻžāĻā§āϰ āĻāύā§āϝ āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
B. Calcium Carbonate
āĻāĻāĻŋ calcium-āĻāϰ āĻāĻāĻāĻŋ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻā§āϏāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻāĻžāĻĻā§āϝ āĻŦāĻž āĻāώā§āϧā§āϰ āĻŽāĻžāϧā§āϝāĻŽā§ āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽ āϏāϰāĻŦāϰāĻžāĻš āĻāϰ⧠āĻļāϰā§āϰā§āϰ āĻĒā§āϰāϝāĻŧā§āĻāύā§āϝāĻŧ calcium balance āĻŦāĻāĻžāϝāĻŧ āϰāĻžāĻāϤ⧠āϏāĻžāĻšāĻžāϝā§āϝ āĻāϰā§āĨ¤
C. Vitamin C
Vitamin C collagen synthesis-āĻāϰ āĻāύā§āϝ āĻĒā§āϰāϝāĻŧā§āĻāύā§āϝāĻŧ cofactorāĨ¤
āĻŦāĻžāĻāϞāĻž: Collagen āϤā§āϰāĻŋāϤ⧠āĻāĻŋāĻāĻžāĻŽāĻŋāύ C āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤ Collagen āĻšāĻžāĻĄāĻŧ, āϞāĻŋāĻāĻžāĻŽā§āύā§āĻ, āϤā§āĻŦāĻ āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ connective tissue-āĻāϰ āĻāĻ āύāĻāϤ āĻāĻĒāĻžāĻĻāĻžāύāĨ¤
12. Drug Indications / āĻā§āύ āĻā§āύ āϰā§āĻā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻšāϝāĻŧ?
1. Calcium Deficiency â āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽā§āϰ āĻāĻžāĻāϤāĻŋāĨ¤
2. Vitamin C Deficiency â āĻāĻŋāĻāĻžāĻŽāĻŋāύ C-āĻāϰ āĻāĻžāĻāϤāĻŋāĨ¤
3. Osteoporosis â āĻšāĻžāĻĄāĻŧā§āϰ āĻāύāϤā§āĻŦ āĻāĻŽā§ āϝāĻžāĻāϝāĻŧāĻž, āϝā§āĻāĻžāύ⧠āĻĒāϰā§āϝāĻžāĻĒā§āϤ calcium intake āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āϏāĻšāĻžāϝāĻŧāĻ āĻ āĻāĻļ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
4. Increased Calcium Requirement â āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽā§āϰ āĻāĻžāĻšāĻŋāĻĻāĻž āĻŦā§āĻĻā§āϧāĻŋ, āϝā§āĻŽāύ āĻāĻŋāĻā§ āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž, āϏā§āϤāύā§āϝāĻĻāĻžāύ āĻŦāĻž āĻŦā§āĻĻā§āϧ āĻŦāϝāĻŧāϏā§āϰ āĻĒāϰāĻŋāϏā§āĻĨāĻŋāϤāĻŋāĨ¤
5. Nutritional Deficiency During Recovery â āĻ āϏā§āϏā§āĻĨāϤāĻžāϰ āĻĒāϰ āĻĒā§āώā§āĻāĻŋāĻāϤ āĻāĻžāĻāϤāĻŋāĨ¤
6. Postmenopausal Nutritional Support â āĻŽā§āύā§āĻĒāĻ-āĻĒāϰāĻŦāϰā§āϤ⧠āĻĒā§āώā§āĻāĻŋāĻāϤ āϏāĻšāĻžāϝāĻŧāϤāĻžāĨ¤
13. Drug Interaction + Contraindications
Drug Interactions
Tetracycline Antibiotics: āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽ antibiotic absorption āĻāĻŽāĻžāϤ⧠āĻĒāĻžāϰā§āĨ¤
Digoxin: Calcium imbalance āĻĨāĻžāĻāϞ⧠cardiac toxicity-āĻāϰ āĻā§āĻāĻāĻŋ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāϝāĻŧāĨ¤
Thiazide Diuretics: Hypercalcemia-āĻāϰ āĻā§āĻāĻāĻŋ āĻŦāĻžāĻĄāĻŧāϤ⧠āĻĒāĻžāϰā§āĨ¤
Levothyroxine: Calcium levothyroxine-āĻāϰ āĻļā§āώāĻŖ āĻāĻŽāĻžāϝāĻŧ; āϏāĻžāϧāĻžāϰāĻŖāϤ āĻāϞāĻžāĻĻāĻž āϏāĻŽāϝāĻŧā§ āĻā§āϰāĻšāĻŖ āĻāϰāϤ⧠āĻšāϝāĻŧāĨ¤
Iron Supplement: Calcium āĻāĻŋāĻā§ āĻĒāϰāĻŋāϏā§āĻĨāĻŋāϤāĻŋāϤ⧠iron absorption-āĻ āĻĒā§āϰāĻāĻžāĻŦ āĻĢā§āϞāϤ⧠āĻĒāĻžāϰā§āĨ¤
Contraindications
Hypercalcemia â āϰāĻā§āϤ⧠āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽāĨ¤
Severe Hypercalciuria â āĻĒā§āϰāϏā§āϰāĻžāĻŦā§ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽāĨ¤
Severe Renal Failure â āĻā§āϰā§āϤāϰ āĻāĻŋāĻĄāύāĻŋ āĻ āĻāĻžāϰā§āϝāĻāĻžāϰāĻŋāϤāĻžāĨ¤
Certain Disorders of Calcium Metabolism â āĻā§āϝāĻžāϞāϏāĻŋāϝāĻŧāĻžāĻŽ āĻŦāĻŋāĻĒāĻžāĻā§āϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰā§āĻāĨ¤
14. Precautions & Warnings
āĻāĻŋāĻĄāύāĻŋāϤ⧠āĻĒāĻžāĻĨāϰā§āϰ āĻāϤāĻŋāĻšāĻžāϏ, renal impairment, hypercalcemia-āĻāϰ āĻā§āĻāĻāĻŋ āĻāĻŦāĻ āĻ āύā§āϝ calcium-containing supplement āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻŦāĻŋāώāϝāĻŧ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
āϝāĻžāĻĻā§āϰ āĻĄāĻžāϝāĻŧāĻžāĻŦā§āĻāĻŋāϏ āϰāϝāĻŧā§āĻā§ āϤāĻžāĻĻā§āϰ effervescent formulation-āĻāϰ excipients āĻ sugar content āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
15. Dosage & Administration
MedEx Adult Reference Dose:
1 effervescent tablet once daily.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰāĻžāĻĒā§āϤāĻŦāϝāĻŧāϏā§āĻāĻĻā§āϰ āĻāύā§āϝ āϰā§āĻĢāĻžāϰā§āύā§āϏ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āĻĻāĻŋāύ⧠āĻāĻāĻāĻŋ effervescent tabletāĨ¤
Administration: Dissolve one tablet completely in a glass of water before drinking.
āĻŦāĻžāĻāϞāĻž: āĻāĻāĻāĻŋ āĻā§āϝāĻžāĻŦāϞā§āĻ āĻāĻ āĻā§āϞāĻžāϏ āĻĒāĻžāύāĻŋāϤ⧠āϏāĻŽā§āĻĒā§āϰā§āĻŖ āĻā§āϞāĻŋāϝāĻŧā§ āĻĒāĻžāύ āĻāϰāϤ⧠āĻšāϝāĻŧāĨ¤
āĻā§āĻŦ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ: āϏāĻžāϧāĻžāϰāĻŖ āĻā§āϝāĻžāĻŦāϞā§āĻā§āϰ āĻŽāϤ⧠āϏāϰāĻžāϏāϰāĻŋ āĻāĻŋāϞ⧠āĻāĻžāĻāϝāĻŧāĻžāϰ āĻāύā§āϝ āĻāĻāĻŋ āϤā§āϰāĻŋ āύāϝāĻŧāĨ¤
16. Pregnancy & Lactation
Calcium āĻ Vitamin C āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻŽāĻžāϤā§āϰāĻžāϝāĻŧ āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻāĻŦāĻ āϏā§āϤāύā§āϝāĻĻāĻžāύā§āϰ āϏāĻŽāϝāĻŧ āĻĒā§āϰāϝāĻŧā§āĻāύā§āϝāĻŧ āĻĒā§āώā§āĻāĻŋ āĻāĻĒāĻžāĻĻāĻžāύāĨ¤
āϤāĻŦā§ supplements āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻā§ āĻŽā§āĻ āĻĻā§āύāĻŋāĻ calcium āĻ vitamin C intake, āĻāĻžāĻĻā§āϝāĻžāĻā§āϝāĻžāϏ āĻāĻŦāĻ renal risk āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
Pregnancy: Clinically indicated āĻšāϞ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
Lactation: āĻāĻĒāϝā§āĻā§āϤ nutritional requirement āĻ āύā§āϝāĻžāϝāĻŧā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āϝāĻžāϝāĻŧāĨ¤
MedEx Verification Confidence: 0.99
𩷠SECTION 08 | BANGLADESH DOCTORS’ DRUG LIST â MEDEX āĻ āύā§āϝāĻžāϝāĻŧā§
Low Back Pain-āĻ āĻĒā§āϰāĻžāϏāĻā§āĻāĻŋāĻ āĻāώā§āϧā§āϰ āϤāĻžāϞāĻŋāĻāĻž
Clinical Note: āύāĻŋāĻā§āϰ āϤāĻžāϞāĻŋāĻāĻž āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļā§ āĻĒāĻžāĻāϝāĻŧāĻž āϝāĻžāϝāĻŧ āĻāĻŽāύ āĻāώā§āϧā§āϰ āĻāĻĻāĻžāĻšāϰāĻŖāĨ¤ āϏāĻŦ āĻāώā§āϧ āĻāĻāĻ āϰā§āĻā§āĻā§ āĻĻāĻŋāϤ⧠āĻšāĻŦā§âāĻāĻŽāύ āύāϝāĻŧāĨ¤ āĻāώā§āϧ āĻŦāĻžāĻāĻžāĻ āύāĻŋāϰā§āĻāϰ āĻāϰ⧠āϰā§āĻā§āϰ āϧāϰāύ, clinical indication āĻ āĻā§āĻāĻāĻŋāϰ āĻāĻĒāϰāĨ¤
| No. | Generic | Bangladesh Brand | MedEx Therapeutic Class | Unit Price | 10-Unit Price | Clinical Purpose |
|---|---|---|---|---|---|---|
| 1 | Aceclofenac 100 mg | Flexi | NSAIDs; Drugs for OA/RA | ā§ŗ7.00 | ā§ŗ70.00 | Pain/inflammation â āĻŦā§āϝāĻĨāĻž āĻ āĻĒā§āϰāĻĻāĻžāĻš |
| 2 | Naproxen Sodium 250 mg | Naprox | NSAIDs | ā§ŗ7.00 | ā§ŗ70.00 | Alternative NSAID |
| 3 | Etoricoxib 90 mg | Etorix | Selective COX-2 Inhibitors / NSAIDs | ā§ŗ12.00 | ā§ŗ120.00 | Selected approved inflammatory pain indications |
| 4 | Paracetamol 500 mg | Napa | Non-opioid Analgesic & Antipyretic | ā§ŗ1.20 | ā§ŗ12.00 | Analgesic; not recommended alone for nonspecific LBP |
| 5 | Tizanidine 2 mg | Relentus | Centrally Acting Skeletal Muscle Relaxants | ā§ŗ8.00 | ā§ŗ80.00 | Selected painful muscle spasm |
| 6 | Omeprazole 20 mg | Seclo | Proton Pump Inhibitor | ā§ŗ6.00 | ā§ŗ60.00 | Selected GI protection |
| 7 | Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C | Sante | Specific Mineral & Vitamin Combined Preparations | ā§ŗ15.00 | ā§ŗ150.00 | Calcium/Vitamin C supplementation |
Pricing: MedEx-listed unit āĻ pack prices; āϏā§āĻĨāĻžāύā§āϝāĻŧ āĻĢāĻžāϰā§āĻŽā§āϏāĻŋāϤ⧠āĻŽā§āϞā§āϝ āĻ availability āĻĒāϰāĻŋāĻŦāϰā§āϤāĻŋāϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Key Clinical Drug Selection Principles
NSAID: Selected uncomplicated LBP-āĻāϰ āĻā§āώā§āϤā§āϰ⧠āĻĒā§āϰāĻĨāĻŽ āϏāĻžāϰāĻŋāϰ pharmacological option āĻšāĻŋāϏā§āĻŦā§ āĻŦāĻŋāĻŦā§āĻā§āϝāĨ¤
Muscle Relaxant: Routine treatment āύāϝāĻŧ; āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ painful spasm āĻĨāĻžāĻāϞ⧠āϏā§āĻŦāϞā§āĻĒāĻŽā§āϝāĻŧāĻžāĻĻāĻŋ riskâbenefit assessment āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
PPI: NSAID-associated GI risk āĻ āύā§āϝāĻžāϝāĻŧā§ āĻŦāĻŋāĻŦā§āĻāύāĻžāĨ¤
Sante: Calcium/Vitamin C supplementation-āĻāϰ āĻĒā§āϰāϝāĻŧā§āĻāύ āĻĨāĻžāĻāϞ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰāĨ¤ āϏāĻžāϧāĻžāϰāĻŖ āĻā§āĻŽāϰāĻŦā§āϝāĻĨāĻžāϰ āĻāύā§āϝ āύāĻŋāĻā§ āĻĨā§āĻā§ āύāĻŋāϝāĻŧāĻŽāĻŋāϤ āĻĒā§āϰāϝāĻŧā§āĻāύā§āϝāĻŧ āύāϝāĻŧāĨ¤
Etoricoxib: āĻāĻŦāĻŋāϰ āϰā§āĻā§āϰ nonspecific LBP-āĻāϰ āĻāύā§āϝ āύāĻŋāϝāĻŧāĻŽāĻŋāϤ first-line medicine āĻšāĻŋāϏā§āĻŦā§ āĻĻā§āĻāĻžāύ⧠āĻāĻāĻŋāϤ āύāϝāĻŧ; āĻ āύā§āĻŽā§āĻĻāĻŋāϤ indication āĻ cardiovascular risk āĻ āύā§āϏāĻžāϰ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāϤ⧠āĻšāϝāĻŧāĨ¤
Avoid Duplicate NSAIDs: Flexi + Naprox + Etorix āĻāĻāĻ āϏāĻā§āĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻāĻāĻŋāϤ āύāϝāĻŧāĨ¤
Guideline Confidence: 0.97
đ¨ SECTION 09 | MY CLINICAL WORKING ASSESSMENT / āĻāĻŽāĻžāϰ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āϰā§āĻāύāĻŋāϰā§āĻŖāϝāĻŧ
đĒ A. Provisional Diagnosis / āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰā§āĻāύāĻŋāϰā§āĻŖāϝāĻŧ
Primary Working Diagnosis
Low Back Pain (LBP), Etiology Undetermined.
āĻŦāĻžāĻāϞāĻž: āĻā§āĻŽāϰā§āϰ āύāĻŋāĻā§āϰ āĻ āĻāĻļā§ āĻŦā§āϝāĻĨāĻž, āϝāĻžāϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāĻžāϰāĻŖ āĻāĻāύ⧠āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āύāϝāĻŧāĨ¤
Possible Underlying Condition
Suspected Nonspecific Mechanical Low Back Pain with Possible Lumbar Muscle Spasm.
āĻŦāĻžāĻāϞāĻž: āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋ āĻŦāĻž āĻŽā§āϰā§āĻĻāĻŖā§āĻĄā§āϰ āϝāĻžāύā§āϤā§āϰāĻŋāĻ āĻāĻžāϰāĻŖā§ āĻā§āĻŽāϰāĻŦā§āϝāĻĨāĻž, āϝāĻžāϰ āϏāĻā§āĻā§ āĻĒā§āĻļāĻŋāϰ āĻāĻžāύ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Important Differential to Exclude if Indicated
Lumbar Radiculopathy â āĻā§āĻŽāϰā§āϰ āϏā§āύāĻžāϝāĻŧā§āĻŽā§āϞ āĻāĻā§āϰāĻžāύā§āϤ āĻšāĻāϝāĻŧāĻžāĨ¤
āĻĒāĻžāϝāĻŧā§ āĻāĻĄāĻŧāĻžāύ⧠āĻŦā§āϝāĻĨāĻž, āĻāĻŋāύāĻāĻŋāύāĻŋ, āĻ āĻŦāĻļāĻāĻžāĻŦ āĻŦāĻž āĻĒā§āĻļāĻŋāϰ āĻĻā§āϰā§āĻŦāϞāϤāĻž āĻĨāĻžāĻāϞ⧠āĻāĻ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Why This Diagnosis?
Clinical Evidence 01: Prescribed notation probably indicates LBP.
Clinical Evidence 02: Flexi is used for pain and inflammation, including lumbago.
Clinical Evidence 03: Relentus may have been prescribed for suspected painful muscle spasm.
Clinical Evidence 04: Seclo may have been prescribed for gastroprotection with NSAID use.
Clinical Evidence 05: Sante suggests a possible supplementation plan, not a definitive diagnosis of metabolic bone disease.
Interpretation
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āϤāĻĨā§āϝ symptom-level diagnosis āϏāĻŽāϰā§āĻĨāύ āĻāϰā§āĨ¤
āĻāĻŋāύā§āϤ⧠āĻā§āύ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ structural spinal disease āĻļāύāĻžāĻā§āϤ āĻāϰāĻžāϰ āĻŽāϤ⧠clinical evidence āύā§āĻāĨ¤
Provisional Diagnosis Confidence: 0.78
đĒ B. Specialist Referral / āĻā§āύ āĻŦāĻŋāĻļā§āώāĻā§āĻā§āϰ āĻāĻžāĻā§ āĻĒāĻžāĻ āĻžāϤ⧠āĻšāĻŦā§?
First Choice
Orthopedics Specialist â āĻ āϰā§āĻĨā§āĻĒā§āĻĄāĻŋāĻā§āϏ āĻŦāĻŋāĻļā§āώāĻā§āĻāĨ¤
Alternative
Physical Medicine & Rehabilitation Specialist â āĻĢāĻŋāĻāĻŋāĻā§āϝāĻžāϞ āĻŽā§āĻĄāĻŋāϏāĻŋāύ āĻ āĻĒā§āύāϰā§āĻŦāĻžāϏāύ āĻŦāĻŋāĻļā§āώāĻā§āĻāĨ¤
āĻŦā§āϝāĻĨāĻžāϰ āϏāĻā§āĻā§ āĻāĻžāϰā§āϝāĻā§āώāĻŽāϤāĻžāϰ āϏāĻŽāϏā§āϝāĻž āĻĨāĻžāĻāϞ⧠exercise-based rehabilitation āĻĒāϰāĻŋāĻāϞā§āĻĒāύāĻžāϰ āĻāύā§āϝ āĻāĻĒāϝā§āĻā§āĨ¤
Emergency Referral
āύāϤā§āύ bladder dysfunction, saddle anesthesia āĻŦāĻž progressive neurological weakness āĻĨāĻžāĻāϞ⧠āĻāϰā§āϰāĻŋ spinal/neurosurgical assessment āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
Referral Confidence: 0.97
đ§ C. Diagnostic Conclusion / āĻā§āĻĄāĻŧāĻžāύā§āϤ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ
Most Defensible Prescription-Based Working Diagnosis:
Low Back Pain (LBP), Etiology Undetermined â Suspected Mechanical Origin, Possible Associated Muscle Spasm.
āĻŦāĻžāĻāϞāĻž: āĻāĻžāϰāĻŖ āĻāĻāύ⧠āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āύāϝāĻŧ āĻāĻŽāύ āĻā§āĻŽāϰā§āϰ āύāĻŋāĻā§āϰ āĻ āĻāĻļā§āϰ āĻŦā§āϝāĻĨāĻž; āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϝāĻžāύā§āϤā§āϰāĻŋāĻ āĻāĻžāϰāĻŖ āĻ āĻĒā§āĻļāĻŋāϰ āĻāĻžāύ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Does Sante Change the Diagnosis?
No.
Sante āϝā§āĻā§āϤ āĻšāĻāϝāĻŧāĻžāϰ āĻĢāϞ⧠prescription interpretation-āĻ possible calcium/vitamin C supplementation āĻ āύā§āϤāϰā§āĻā§āĻā§āϤ āĻšāĻā§āĻā§āĨ¤
āĻāĻŋāύā§āϤ⧠osteoporosis, calcium deficiency āĻŦāĻž osteomalacia-āĻāϰ āϰā§āĻāύāĻŋāϰā§āĻŖāϝāĻŧ āĻāϰāĻžāϰ āϝāĻĨā§āώā§āĻ āĻĒā§āϰāĻŽāĻžāĻŖ āϤā§āϰāĻŋ āĻšāĻā§āĻā§ āύāĻžāĨ¤
Diagnostic Conclusion Confidence: 0.89
đĸ SECTION 10 | Definition, Etiology & Pathophysiology / āϏāĻāĻā§āĻāĻž, āĻāĻžāϰāĻŖ āĻ āϰā§āĻā§āϰ āĻāĻžāϰā§āϝāĻĒāĻĻā§āϧāϤāĻŋ
10.1 Definition â āϏāĻāĻā§āĻāĻž
Low Back Pain āĻšāϞ⧠āĻĒāĻŋāĻ ā§āϰ āύāĻŋāĻā§āϰ āĻ āĻāĻļā§ āĻŦā§āϝāĻĨāĻž āĻŦāĻž āĻ āϏā§āĻŦāϏā§āϤāĻŋ, āϝāĻž āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋ, āϞāĻŋāĻāĻžāĻŽā§āύā§āĻ, āĻĄāĻŋāϏā§āĻ, āĻ āϏā§āĻĨāĻŋāϏāύā§āϧāĻŋ āĻŦāĻž āĻ āύā§āϝāĻžāύā§āϝ pain-sensitive structure āĻĨā§āĻā§ āĻā§āĻĒāύā§āύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
10.2 Etiology â āĻāĻžāϰāĻŖ
Mechanical Causes / āϝāĻžāύā§āϤā§āϰāĻŋāĻ āĻāĻžāϰāĻŖ
Lumbar Muscle Strain: āĻā§āĻŽāϰā§āϰ āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋāϤ⧠āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻāĻžāύ āĻŦāĻž āĻāĻāĻžāϤāĨ¤
Ligament Sprain: āĻā§āĻŽāϰā§āϰ ligament āĻā§āώāϤāĻŋāĻā§āϰāϏā§āϤ āĻšāĻāϝāĻŧāĻžāĨ¤
Nonspecific Musculoskeletal Pain: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻā§āύ⧠structural lesion āĻļāύāĻžāĻā§āϤ āύāĻž āĻšāϞā§āĻ āĻā§āĻŽāϰāĻŦā§āϝāĻĨāĻžāĨ¤
Degenerative Changes: āĻŦāϝāĻŧāϏ āĻŦāĻž āĻ āύā§āϝāĻžāύā§āϝ āĻāĻžāϰāĻŖā§ āĻŽā§āϰā§āĻĻāĻŖā§āĻĄā§āϰ āĻāĻ āύāĻāϤ āĻā§āώāϝāĻŧāĨ¤
Neurological Causes / āϏā§āύāĻžāϝāĻŧāĻŦāĻŋāĻ āĻāĻžāϰāĻŖ
Lumbar Disc Herniation: āĻĄāĻŋāϏā§āĻā§āϰ āĻ āĻāĻļ āĻŦāĻžāĻāϰ⧠āĻŦā§āϰāĻŋāϝāĻŧā§ āϏā§āύāĻžāϝāĻŧā§āĻŽā§āϞ⧠āĻāĻžāĻĒ āĻŦāĻž āĻĒā§āϰāĻĻāĻžāĻš āϏā§āώā§āĻāĻŋ āĻāϰāĻžāĨ¤
Lumbar Radiculopathy: āĻā§āĻŽāϰā§āϰ nerve root āĻāĻā§āϰāĻžāύā§āϤ āĻšāĻāϝāĻŧāĻžāĨ¤
Inflammatory Causes / āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āĻāĻžāϰāĻŖ
Axial Spondyloarthritis: āĻŽā§āϰā§āĻĻāĻŖā§āĻĄ āĻ sacroiliac joint-āĻāϰ āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āϰā§āĻāĨ¤
Serious Causes / āĻā§āϰā§āϤāϰ āĻāĻžāϰāĻŖ
Vertebral fracture, spinal infection, malignancy āĻŦāĻž cauda equina syndromeāĨ¤
10.3 Pathophysiology â āϰā§āĻā§āϰ āĻāĻžāϰā§āϝāĻĒāĻĻā§āϧāϤāĻŋ
Mechanical LBP-āĻ āĻŦāĻŋāĻāĻŋāύā§āύ pain-sensitive tissue āĻĨā§āĻā§ nociceptive signals āϤā§āϰāĻŋ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Nociception: āĻā§āώāϤāĻŋāĻāϰ āĻŦāĻž āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻā§āώāϤāĻŋāĻāϰ āĻāĻĻā§āĻĻā§āĻĒāύāĻžāϰ āĻĢāϞ⧠āĻŦā§āϝāĻĨāĻžāϰ āϏāĻāĻā§āϤ āϤā§āϰāĻŋ āĻšāĻāϝāĻŧāĻžāϰ āĻĒā§āϰāĻā§āϰāĻŋāϝāĻŧāĻžāĨ¤
Inflammatory Mediators: Prostaglandins āĻ āĻ āύā§āϝāĻžāύā§āϝ inflammatory mediators āĻŦā§āϝāĻĨāĻžāϰ āϏāĻāĻŦā§āĻĻāύ āĻŦāĻžāĻĄāĻŧāĻžāϤ⧠āĻĒāĻžāϰā§āĨ¤
Muscle Spasm: āĻāĻŋāĻā§ āĻā§āώā§āϤā§āϰ⧠āĻŦā§āϝāĻĨāĻž āĻ protective muscle contraction āĻāĻā§ āĻ āύā§āϝāĻā§ āĻĒā§āϰāĻāĻžāĻŦāĻŋāϤ āĻāϰ⧠āĻ āϏā§āĻŦāϏā§āϤāĻŋ āĻŦāĻžāĻĄāĻŧāĻžāϤ⧠āĻĒāĻžāϰā§āĨ¤
Pathophysiology Confidence: 0.98 â āϏāĻžāϧāĻžāϰāĻŖ āϰā§āĻāϤāϤā§āϤā§āĻŦ; āĻāĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ mechanism āĻĒā§āϰāĻŽāĻžāĻŖāĻŋāϤ āύāϝāĻŧāĨ¤
đĸ SECTION 11 | Clinical Features & Symptoms / āϰā§āĻā§āϰ āϞāĻā§āώāĻŖ
Typical Features of Mechanical Low Back Pain
Localized Lumbar Pain: āĻā§āĻŽāϰā§āϰ āύāĻŋāĻā§ āϏā§āĻĨāĻžāύā§āϝāĻŧ āĻŦā§āϝāĻĨāĻžāĨ¤
Pain with Movement: āύāĻĄāĻŧāĻžāĻāĻĄāĻŧāĻžāϝāĻŧ āĻŦā§āϝāĻĨāĻž āĻŦā§āĻĻā§āϧāĻŋāĨ¤
Muscle Tenderness: āĻĒā§āĻļāĻŋāϤ⧠āĻāĻžāĻĒ āĻĻāĻŋāϞ⧠āĻŦā§āϝāĻĨāĻžāĨ¤
Reduced Range of Motion: āĻā§āĻŽāϰ āύāĻĄāĻŧāĻžāĻāĻĄāĻŧāĻžāϰ āϏā§āĻŽāĻžāĻŦāĻĻā§āϧāϤāĻžāĨ¤
Features Suggesting Radiculopathy
Radiating Leg Pain: āĻĒāĻžāϝāĻŧā§āϰ āĻĻāĻŋāĻā§ āĻāĻĄāĻŧāĻžāύ⧠āĻŦā§āϝāĻĨāĻžāĨ¤
Paresthesia: āĻāĻŋāύāĻāĻŋāύāĻŋ āĻ āύā§āĻā§āϤāĻŋāĨ¤
Numbness: āĻ āĻŦāĻļāĻāĻžāĻŦāĨ¤
Motor Weakness: āĻĒā§āĻļāĻŋāϰ āĻļāĻā§āϤāĻŋ āĻāĻŽā§ āϝāĻžāĻāϝāĻŧāĻžāĨ¤
Red Flag Symptoms / āĻāϰā§āϰāĻŋ āĻŦāĻŋāĻĒāĻā§āĻāύāĻ āϞāĻā§āώāĻŖ
āύāĻŋāĻā§āϰ āϞāĻā§āώāĻŖāĻā§āϞ⧠āĻĨāĻžāĻāϞ⧠āĻĻā§āϰā§āϤ āĻāĻŋāĻāĻŋā§āϏāĻž āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰā§āϰāĻŋ:
- New urinary retention or incontinence â āύāϤā§āύ āĻĒā§āϰāϏā§āϰāĻžāĻŦ āĻāĻāĻā§ āϝāĻžāĻāϝāĻŧāĻž āĻŦāĻž āύāĻŋāϝāĻŧāύā§āϤā§āϰāĻŖ āĻšāĻžāϰāĻžāύā§āĨ¤
- Saddle anesthesia â āϝā§āύāĻžāĻā§āĻ āĻŦāĻž āĻĒāĻžāϝāĻŧā§āĻĒāĻĨā§āϰ āĻāĻļāĻĒāĻžāĻļā§ āĻ āύā§āĻā§āϤāĻŋ āĻāĻŽā§ āϝāĻžāĻāϝāĻŧāĻžāĨ¤
- Progressive leg weakness â āĻĒāĻžāϝāĻŧā§āϰ āĻĻā§āϰā§āĻŦāϞāϤāĻž āĻā§āϰāĻŽāĻžāĻāϤ āĻŦā§āĻĻā§āϧāĻŋāĨ¤
- Fever with severe back pain â āϤā§āĻŦā§āϰ āĻā§āĻŽāϰāĻŦā§āϝāĻĨāĻžāϰ āϏāĻā§āĻā§ āĻā§āĻŦāϰāĨ¤
- Major trauma â āĻŦāĻĄāĻŧ āĻāĻāĻžāϤāĨ¤
- Known malignancy with new unexplained back pain â āĻā§āϝāĻžāύā§āϏāĻžāϰā§āϰ āĻāϤāĻŋāĻšāĻžāϏāϏāĻš āύāϤā§āύ āĻ āĻāĻžāϰāĻŖ āĻā§āĻŽāϰāĻŦā§āϝāĻĨāĻžāĨ¤
Clinical Confidence: 0.98
đĸ SECTION 12 | Differential Diagnosis / āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻ āύā§āϝāĻžāύā§āϝ āϰā§āĻ
| Diagnosis | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ | Supporting Evidence | Assessment Confidence |
|---|---|---|---|
| Nonspecific Low Back Pain | āĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāĻžāϰāĻŖā§āϰ āĻā§āĻŽāϰāĻŦā§āϝāĻĨāĻž | Probable LBP notation | 0.78 |
| Mechanical Low Back Pain | āϝāĻžāύā§āϤā§āϰāĻŋāĻ āĻāĻžāϰāĻŖā§ āĻā§āĻŽāϰāĻŦā§āϝāĻĨāĻž | Possible musculoskeletal treatment pattern | 0.68 |
| Lumbar Muscle Spasm | āĻā§āĻŽāϰā§āϰ āĻĒā§āĻļāĻŋāϤ⧠āĻāĻŋāĻāĻā§āύāĻŋ | Possible Relentus use | 0.61 |
| Lumbar Radiculopathy | āĻā§āĻŽāϰā§āϰ āϏā§āύāĻžāϝāĻŧā§āĻŽā§āϞ āĻāĻā§āϰāĻžāύā§āϤ āĻšāĻāϝāĻŧāĻž | Radicular symptoms undocumented | 0.42 |
| Lumbar Disc Herniation | āĻā§āĻŽāϰā§āϰ āĻĄāĻŋāϏā§āĻ āĻŦā§āϰāĻŋāϝāĻŧā§ āĻāϏāĻž | No imaging or neurological findings | 0.30 |
| Lumbar Spondylosis | āĻā§āĻŽāϰā§āϰ āĻŽā§āϰā§āĻĻāĻŖā§āĻĄā§āϰ āĻā§āώāϝāĻŧ | No confirmatory history or imaging | 0.30 |
| Osteoporosis | āĻšāĻžāĻĄāĻŧā§āϰ āĻāύāϤā§āĻŦ āĻāĻŽā§ āϝāĻžāĻāϝāĻŧāĻž | Sante alone is insufficient evidence | 0.20 |
| Osteomalacia | āĻšāĻžāĻĄāĻŧā§āϰ āĻāύāĻŋāĻāĻžāϝāĻŧāύ⧠āϏāĻŽāϏā§āϝāĻž | No metabolic assessment | 0.15 |
Interpretation: 0.40-āĻāϰ āύāĻŋāĻā§āϰ diagnosisāĻā§āϞ⧠āĻŦāϰā§āϤāĻŽāĻžāύ⧠evidence-supported working diagnosis āĻšāĻŋāϏā§āĻŦā§ āĻā§āϰāĻšāĻŖāϝā§āĻā§āϝ āύāϝāĻŧāĨ¤ āĻāĻā§āϞ⧠āĻļā§āϧ⧠āĻĒā§āϰāϝāĻŧā§āĻāύ āĻ āύā§āϝāĻžāϝāĻŧā§ differential considerationāĨ¤
đĸ SECTION 13 | DOCTOR’S DX vs MY DX â CLINICAL COMPARISON
đĸ Similarities / āĻŽāĻŋāϞ
1. Doctor’s Probable Dx: LBP â Low Back PaināĨ¤
My Dx: Low Back Pain, Etiology UndeterminedāĨ¤
Similarity: āĻŽā§āϞ āĻāĻĒāϏāϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻŽāĻŋāϞ āϰāϝāĻŧā§āĻā§āĨ¤
2. Prescribed Analgesic: FlexiāĨ¤
My Interpretation: āĻā§āĻŽāϰāĻŦā§āϝāĻĨāĻžāϰ symptomatic treatmentāĨ¤
Similarity: āĻŦā§āϝāĻĨāĻž āĻāĻĒāĻļāĻŽā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝā§āϰ āϏāĻā§āĻā§ āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖāĨ¤
3. Possible Muscle Relaxant: RelentusāĨ¤
My Interpretation: Muscle spasm āϏāύā§āĻĻā§āĻšā§ prescribing āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Similarity: āϏāĻŽā§āĻāĻžāĻŦā§āϝ musculoskeletal treatment strategy-āĻāϰ āϏāĻā§āĻā§ āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖāĨ¤
đ§ Differences / āĻ āĻŽāĻŋāϞ
1. Mechanical Origin: āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āύā§āĻā§ āύāĻŋāĻļā§āĻāĻŋāϤāĻāĻžāĻŦā§ āϞā§āĻāĻž āύā§āĻ; āĻāĻŽāĻžāϰ assessment-āĻ āĻāĻāĻŋ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻžāϰāĻŖāĨ¤
2. Lumbar Muscle Spasm: āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ examination finding āύā§āĻ; āĻāώā§āϧā§āϰ āĻŽāĻžāϧā§āϝāĻŽā§ āϏāύā§āĻĻā§āĻš āĻāϰāĻž āĻšāϝāĻŧā§āĻā§āĨ¤
3. Calcium Deficiency/Osteoporosis: Sante āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻžāϰāĻŖā§ āϰā§āĻāύāĻŋāϰā§āĻŖāϝāĻŧ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
4. Lumbar Radiculopathy: āϏā§āύāĻžāϝāĻŧāĻŦāĻŋāĻ āϞāĻā§āώāĻŖā§āϰ āϤāĻĨā§āϝ āĻāĻžāĻĄāĻŧāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Final Comparison Table
| Clinical Parameter | Doctor’s Documentation | My Working Assessment |
|---|---|---|
| Main Diagnosis | Probable LBP | LBP |
| Etiology | Not documented | Undetermined |
| Mechanical Origin | Not confirmed | Suspected |
| Muscle Spasm | Not documented | Possible |
| Calcium Deficiency | Not documented | Not established |
| Osteoporosis | Not documented | Not established |
| Radiculopathy | Not documented | Requires clinical evidence |
| Diagnostic Status | Symptom-level | Provisional |
đĸ Final Similarity
Doctor’s probable diagnosis and my working diagnosis are consistent at the level of Low Back Pain.
đ§ Final Difference
āĻāĻŽāĻžāϰ assessment-āĻ āĻāĻŋāĻā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻžāϰāĻŖā§āϰ āĻāϞā§āĻāύāĻž āϰāϝāĻŧā§āĻā§, āϝāĻž āĻāĻāύ⧠āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āύāĻĨāĻŋāĻā§āĻā§āϤ examination āĻŦāĻž investigation āĻĻā§āĻŦāĻžāϰāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻšāϝāĻŧāύāĻŋāĨ¤
Comparison Confidence: 0.89
đĸ SECTION 14 | Evidence-Based Management / āύāĻŋāϰā§āĻĻā§āĻļāĻŋāĻāĻžāĻāĻŋāϤā§āϤāĻŋāĻ āĻāĻŋāĻāĻŋā§āϏāĻž
14.1 Non-Pharmacological Management
A. Patient Education
āϰā§āĻā§āĻā§ āĻā§āĻŽāϰāĻŦā§āϝāĻĨāĻžāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻžāϰāĻŖ, āĻāĻžāϰā§āϝāĻāϞāĻžāĻĒ āĻāĻŦāĻ expected recovery āϏāĻŽā§āĻĒāϰā§āĻā§ āĻŦā§āĻāĻžāϤ⧠āĻšāĻŦā§āĨ¤
B. Maintain Normal Activity
āϏāĻšāύā§āϝāĻŧ āϏā§āĻŽāĻžāϰ āĻŽāϧā§āϝ⧠āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻāĻžāĻ āĻāĻžāϞāĻŋāϝāĻŧā§ āϝāĻžāĻāϝāĻŧāĻžāϰ āĻĒāϰāĻžāĻŽāϰā§āĻļāĨ¤
C. Exercise Therapy
Clinical assessment āĻ āύā§āϝāĻžāϝāĻŧā§ walking, flexibility exercise āĻāĻŦāĻ progressive strengthening āĻŦāĻŋāĻŦā§āĻāύāĻžāĨ¤
D. Physiotherapy
āĻāĻžāϰā§āϝāĻā§āώāĻŽāϤāĻž āĻāĻŽā§ āĻā§āϞ⧠āĻŦāĻž āĻāĻĒāϏāϰā§āĻ āϏā§āĻĨāĻžāϝāĻŧā§ āĻšāϞ⧠structured exercise-based rehabilitationāĨ¤
E. Avoid Prolonged Bed Rest
āĻĻā§āϰā§āĻāĻĻāĻŋāύ āϏāĻŽā§āĻĒā§āϰā§āĻŖ bed rest āϏāĻžāϧāĻžāϰāĻŖ nonspecific LBP-āĻ āĻāĻĒāĻāĻžāϰ⧠āύāϝāĻŧāĨ¤
14.2 Pharmacological Management
A. NSAIDs
NICE NG59 āĻ āύā§āϝāĻžāϝāĻŧā§ āύāĻŋāϰā§āĻŦāĻžāĻāĻŋāϤ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠oral NSAIDs āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āϝāĻžāϝāĻŧāĨ¤
Principle: Lowest effective dose for the shortest possible duration.
āĻŦāĻžāĻāϞāĻž: āϏāĻŦāĻā§āϝāĻŧā§ āĻāĻŽ āĻāĻžāϰā§āϝāĻāϰ āĻŽāĻžāϤā§āϰāĻž, āϏāĻŦāĻā§āϝāĻŧā§ āĻāĻŽ āĻĒā§āϰāϝāĻŧā§āĻāύā§āϝāĻŧ āϏāĻŽāϝāĻŧāĨ¤
B. Muscle Relaxants
Chronic primary LBP-āĻ routine muscle relaxant therapy WHO 2023 āϏā§āĻĒāĻžāϰāĻŋāĻļ āĻāϰ⧠āύāĻžāĨ¤
C. Proton Pump Inhibitors
NSAID-associated GI risk āĻ āύā§āϝāĻžāϝāĻŧā§ gastroprotection āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
D. Calcium/Vitamin C Supplement
Calcium āĻŦāĻž Vitamin C-āĻāϰ āĻāĻžāĻāϤāĻŋ, dietary insufficiency āĻŦāĻž āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ clinical indication āĻĨāĻžāĻāϞ⧠Sante āĻāĻĒāϝā§āĻā§āϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Routine Sante supplementation solely for nonspecific low back pain is not guideline-established treatment.
E. Avoid Unnecessary Medicines
Duplicate NSAIDs, unnecessary opioids, routine gabapentinoids āĻāĻŦāĻ āĻ āύāĻŋāϰā§āĻĻā§āĻļāĻŋāϤ long-term medication āĻāĻĄāĻŧāĻžāϤ⧠āĻšāĻŦā§āĨ¤
Management Confidence: 0.98
đĸ SECTION 15 | Overview / Summary â āϏāĻžāϰāϏāĻāĻā§āώā§āĻĒ
Prescription Summary
āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϏāĻŽā§āĻāĻŦāϤ Low Back Pain (LBP) āĻāϞā§āϞā§āĻ āϰāϝāĻŧā§āĻā§āĨ¤
āϏāĻāĻļā§āϧāĻŋāϤ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻ āύā§āϝāĻžāϝāĻŧā§ āĻāĻžāϰāĻāĻŋ āĻāώā§āϧ:
1. Flexi 100 mg (Aceclofenac): āĻŦā§āϝāĻĨāĻž āĻ āĻĒā§āϰāĻĻāĻžāĻš āĻāĻŽāĻžāύā§āϰ NSAIDāĨ¤
2. Seclo 20 mg (Omeprazole): āĻĒāĻžāĻāϏā§āĻĨāϞā§āϰ āĻ ā§āϝāĻžāϏāĻŋāĻĄ āĻāĻŽāĻžāύā§āϰ PPI; āϏāĻŽā§āĻāĻžāĻŦā§āϝ gastroprotectionāĨ¤
3. Relentus (Tizanidine): āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋāϰ painful spasm āĻāĻŽāĻžāύā§āϰ āĻāώā§āϧāĨ¤
4. Sante (Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C): Calcium āĻ Vitamin C supplementāĨ¤
Clinical Conclusion
Most Likely Working Diagnosis: Low Back Pain of Undetermined Etiology, with a Possible Mechanical Component.
āĻŦāĻžāĻāϞāĻž: āĻāĻžāϰāĻŖ āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āύāϝāĻŧ āĻāĻŽāύ āĻā§āĻŽāϰāĻŦā§āϝāĻĨāĻž, āϝāĻžāϰ āϏāĻā§āĻā§ āϝāĻžāύā§āϤā§āϰāĻŋāĻ āĻāĻžāϰāĻŖ āĻ āĻĒā§āĻļāĻŋāϰ āĻāĻžāύ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Sante-āĻāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāĻ āϰā§āĻā§āϰ osteoporosis āĻŦāĻž calcium deficiency āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰ⧠āύāĻžāĨ¤
Summary Confidence: 0.89
đĸ SECTION 16 | Actionable Clinical Plan, Prescription Demo & Referral / āĻāĻŋāĻāĻŋā§āϏāĻž āĻĒāϰāĻŋāĻāϞā§āĻĒāύāĻž, āύāĻŽā§āύāĻž āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻ āϰā§āĻĢāĻžāϰ
A. Clinical Action Plan
Step 1 â History Taking: āĻŦā§āϝāĻĨāĻžāϰ āĻļā§āϰā§, āϏā§āĻĨāĻžāϝāĻŧāĻŋāϤā§āĻŦ, āĻĒā§āϰāĻā§āϤāĻŋ, āĻĒāĻžāϝāĻŧā§ āĻāĻĄāĻŧāĻžāϝāĻŧ āĻāĻŋ āύāĻž āĻāĻŦāĻ red flag symptoms āĻāĻžāύāϤ⧠āĻšāĻŦā§āĨ¤
Step 2 â Physical Examination: Lumbar ROM, spinal tenderness, SLR, motor power, sensation āĻ reflex āĻĒāϰā§āĻā§āώāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Step 3 â Risk Assessment: NSAID āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻā§ renal, GI, cardiovascular āĻāĻŦāĻ pregnancy-related risk āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Step 4 â Rational Investigation: Red flag āĻŦāĻž āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ clinical indication āύāĻž āĻĨāĻžāĻāϞ⧠routine MRI/X-ray āĻāĻĄāĻŧāĻžāϤ⧠āĻšāĻŦā§āĨ¤
Step 5 â Treatment Review: Analgesic response, function, adverse effects āĻāĻŦāĻ rehabilitation progress āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Step 6 â Supplement Review: Sante-āĻāϰ āĻĒā§āϰāĻā§āϤ clinical indication āĻāĻā§ āĻāĻŋ āύāĻž āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Action Plan Confidence: 0.98
B. Realistic Clinical Prescription Demonstration
Educational Example â āĻļāĻŋāĻā§āώāĻžāĻŽā§āϞāĻ āύāĻŽā§āύāĻž
āύāĻŋāĻā§āϰ āĻāĻĻāĻžāĻšāϰāĻŖāĻāĻŋ āĻŽā§āϞ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āϰā§āĻā§āϰ āĻāύā§āϝ āύāϝāĻŧāĨ¤
Hypothetical Patient: 35-year-old adult with five days of uncomplicated nonspecific low back pain, normal neurological examination, no red flags, no pregnancy, no renal disease and no NSAID contraindicationsāĨ¤
C/C: Low Back Pain for 5 days â āĻĒāĻžāĻāĻ āĻĻāĻŋāύ āϧāϰ⧠āĻā§āĻŽāϰāĻŦā§āϝāĻĨāĻžāĨ¤
O/E: Lumbar movement-related pain; neurological examination normal â āĻā§āĻŽāϰ āύāĻĄāĻŧāĻžāĻāĻĄāĻŧāĻžāϝāĻŧ āĻŦā§āϝāĻĨāĻž, āϏā§āύāĻžāϝāĻŧāĻŦāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻāĨ¤
Working Dx: Acute Nonspecific Mechanical Low Back Pain â āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϤā§āĻŦā§āϰ āĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϝāĻžāύā§āϤā§āϰāĻŋāĻ āĻā§āĻŽāϰāĻŦā§āϝāĻĨāĻžāĨ¤
Rx â Illustrative Treatment
1. Tab. Aceclofenac 100 mg
For an appropriately selected adult, the reference regimen is 100 mg orally twice daily, for the shortest necessary period, with reassessment and renal/GI/cardiovascular risk reviewāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻāĻĒāϝā§āĻā§āϤ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āϏā§āĻŦāϞā§āĻĒāĻŽā§āϝāĻŧāĻžāĻĻāĻŋ āĻŦā§āϝāĻĨāĻž āύāĻŋāϝāĻŧāύā§āϤā§āϰāĻŖā§ NSAID āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āϝāĻžāϝāĻŧāĨ¤
2. Cap. Omeprazole 20 mg
Consider once daily when gastroprotection is indicated, particularly with relevant NSAID-associated GI riskāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻĒāĻžāĻāϏā§āĻĨāϞā§āϰ āĻāϞāϏāĻžāϰā§āϰ āĻā§āĻāĻāĻŋ āĻ āύā§āϝāĻžāϝāĻŧā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻŦāĻŋāĻŦā§āĻāύāĻžāĨ¤
3. Tab. Tizanidine
Not routinely prescribed in this demonstration. Clinically significant painful spasm āĻĨāĻžāĻāϞ⧠āĻāĻŦāĻ sedation, hypotension āĻ interaction risk āĻŽā§āϞā§āϝāĻžāϝāĻŧāύā§āϰ āĻĒāϰ⧠āĻāĻŋāĻāĻŋā§āϏāĻ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻĒāĻžāϰā§āύāĨ¤
4. Sante Effervescent Tablet
Not routinely prescribed solely for nonspecific back pain.
Documented āĻŦāĻž clinically justified calcium/vitamin C supplementation-āĻāϰ āĻĒā§āϰāϝāĻŧā§āĻāύ āĻĨāĻžāĻāϞ⧠MedEx adult reference āĻ āύā§āϝāĻžāϝāĻŧā§ āĻĻāĻŋāύ⧠āĻāĻāĻāĻŋ tablet āĻĒāĻžāύāĻŋāϤ⧠āĻā§āϞāĻŋāϝāĻŧā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āύā§āĻāϝāĻŧāĻž āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
Advice â āĻĒāϰāĻžāĻŽāϰā§āĻļ
Continue tolerable activity â āϏāĻšāύā§āϝāĻŧ āĻāĻžāĻ āĻāĻžāϞāĻŋāϝāĻŧā§ āϝāĻžāĻāϝāĻŧāĻžāĨ¤
Avoid prolonged bed rest â āĻĻā§āϰā§āĻāĻĻāĻŋāύ āĻŦāĻŋāĻāĻžāύāĻžāϝāĻŧ āĻļā§āϝāĻŧā§ āύāĻž āĻĨāĻžāĻāĻžāĨ¤
Begin appropriate exercises â āĻāĻĒāϝā§āĻā§āϤ āĻŦā§āϝāĻžāϝāĻŧāĻžāĻŽ āĻļā§āϰ⧠āĻāϰāĻžāĨ¤
Return urgently if neurological red flags develop â āύāϤā§āύ āϏā§āύāĻžāϝāĻŧāĻŦāĻŋāĻ āĻŦāĻŋāĻĒāĻā§āĻāύāĻ āϞāĻā§āώāĻŖ āĻĻā§āĻāĻž āĻĻāĻŋāϞ⧠āĻāϰā§āϰāĻŋ āĻāĻŋāĻāĻŋā§āϏāĻž āύā§āĻāϝāĻŧāĻžāĨ¤
Follow-Up
āĻŦā§āϝāĻĨāĻž, āĻĻā§āύāύā§āĻĻāĻŋāύ āĻāĻžāϰā§āϝāĻā§āώāĻŽāϤāĻž, medication response āĻ adverse effects āĻ āύā§āϝāĻžāϝāĻŧā§ āĻĒā§āύāϰā§āĻŽā§āϞā§āϝāĻžāϝāĻŧāύāĨ¤
C. Specific Diagnosis for Clinical Prescription Note
Recommended Working Dx
Dx: Low Back Pain (LBP), Etiology Undetermined â Suspected Nonspecific Mechanical Low Back Pain Âą Lumbar Muscle Spasm.
āĻŦāĻžāĻāϞāĻž: āĻāĻžāϰāĻŖ āĻ āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āĻā§āĻŽāϰāĻŦā§āϝāĻĨāĻž; āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϝāĻžāύā§āϤā§āϰāĻŋāĻ āĻāĻžāϰāĻŖ āĻāĻŦāĻ āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋāϰ āĻāĻžāύ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Referral
Primary: Orthopedics SpecialistāĨ¤
Alternative: Physical Medicine & Rehabilitation SpecialistāĨ¤
Emergency: Suspected cauda equina syndrome āĻŦāĻž progressive neurological deficit āĻĨāĻžāĻāϞ⧠urgent spinal specialist assessmentāĨ¤
Prescription-Note Confidence: 0.91 â āĻāĻāĻāĻŋ conservative, symptom-grounded provisional note āĻšāĻŋāϏā§āĻŦā§ āĻāĻĒāϝā§āĻā§āϤ; āύāĻŋāĻļā§āĻāĻŋāϤ underlying pathology āύāϝāĻŧāĨ¤
đĸ SECTION 17 | REFERENCE LIST â TEXTBOOKS, GUIDELINES & DOI
A. Standard Medical Textbooks
1. Harrison’s Principles of Internal Medicine. 22nd Edition. McGraw Hill; 2025.
Relevant topics: Back pain, neurological assessment, musculoskeletal disordersāĨ¤
2. Davidson’s Principles and Practice of Medicine. 24th Edition. Elsevier; 2022.
Relevant topics: Musculoskeletal medicine and assessment of paināĨ¤
3. Apley’s System of Orthopaedics and Fractures. 10th Edition. CRC Press; 2018.
Relevant topics: Disorders of the spine and low back paināĨ¤
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology.
Relevant chapters: NSAIDs, skeletal muscle relaxants, gastrointestinal pharmacology and mineral supplementationāĨ¤
5. Goodman & Gilman’s The Pharmacological Basis of Therapeutics.
Relevant topics: Anti-inflammatory drugs, gastric acid inhibitors and centrally acting medicationsāĨ¤
Reference Note: āϏā§āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ page number āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻšāϝāĻŧāύāĻŋ, āϤāĻžāĻ āĻ āύā§āĻŽāĻžāύ āĻāϰ⧠page number āĻĻā§āĻāϝāĻŧāĻž āĻšāĻā§āĻā§ āύāĻžāĨ¤
B. International Guidelines
1. NICE NG59
Low Back Pain and Sciatica in Over 16s: Assessment and Management.
Published 2016; pharmacological recommendations amended 2020āĨ¤
NICE NG59 â Official Guideline
2. WHO 2023
WHO Guideline for Non-Surgical Management of Chronic Primary Low Back Pain in Adults.
WHO 2023 â Official Guideline
3. VA/DoD 2022
VA/DoD Clinical Practice Guideline: Diagnosis and Treatment of Low Back Pain.
VA/DoD 2022 â Official Guideline
C. Peer-Reviewed Journals with DOI
1. The Lancet
Hartvigsen J, Hancock MJ, Kongsted A, et al.
What Low Back Pain Is and Why We Need to Pay Attention.
The Lancet. 2018;391(10137):2356â2367.
DOI: 10.1016/S0140-6736(18)30480-X.
Read Journal Article
2. Annals of Internal Medicine
Qaseem A, Wilt TJ, McLean RM, Forciea MA.
Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians.
Ann Intern Med. 2017;166(7):514â530.
DOI: 10.7326/M16-2367.
Read Journal Article
D. MedEx Bangladesh â Official Drug References
| Drug | Verified Generic | MedEx Reference |
|---|---|---|
| Flexi 100 mg | Aceclofenac | Flexi |
| Seclo 20 mg | Omeprazole | Seclo |
| Relentus 2 mg | Tizanidine Hydrochloride | Relentus |
| Sante | Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C | Sante |
đ§ FINAL CLINICAL ASSESSMENT â DIAGNOSTIC VERDICT
1. Doctor’s Probable Diagnosis
Low Back Pain (LBP).
āĻŦāĻžāĻāϞāĻž: āĻā§āĻŽāϰā§āϰ āύāĻŋāĻā§āϰ āĻ āĻāĻļā§ āĻŦā§āϝāĻĨāĻžāĨ¤
2. My Clinical Working Diagnosis
Low Back Pain, Etiology Undetermined â Suspected Nonspecific Mechanical Low Back Pain with Possible Lumbar Muscle Spasm.
āĻŦāĻžāĻāϞāĻž: āĻāĻžāϰāĻŖ āĻ āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āĻā§āĻŽāϰāĻŦā§āϝāĻĨāĻž; āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϝāĻžāύā§āϤā§āϰāĻŋāĻ āĻāĻžāϰāĻŖ āĻ āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋāϰ āĻāĻžāύ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
3. Doctor’s Diagnosis vs My Diagnosis
đĸ Similarity: āĻĒā§āϰāϧāĻžāύ āĻāĻĒāϏāϰā§āĻ Low Back Pain-āĻāϰ āĻā§āώā§āϤā§āϰ⧠āĻŽāĻŋāϞ āϰāϝāĻŧā§āĻā§āĨ¤
đ Difference: Muscle spasm āĻ mechanical origin āĻāĻŽāĻžāϰ differential-based clinical interpretation, confirmed examination findings āύāϝāĻŧāĨ¤
4. Corrected Fourth Medicine
Sante â Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C.
Purpose: Calcium āĻ Vitamin C supplementationāĨ¤
Clinical Interpretation: āĻšāĻžāĻĄāĻŧā§āϰ āϏā§āĻŦāĻžāϏā§āĻĨā§āϝ āĻŦāĻž āĻĒā§āώā§āĻāĻŋāĻāϤ āĻāĻžāĻāϤāĻŋāϰ āϏāĻšāĻžāϝāĻŧāĻ āĻāĻŋāĻāĻŋā§āϏāĻž āĻšāϤ⧠āĻĒāĻžāϰā§; osteoporosis āĻŦāĻž calcium deficiency āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰ⧠āύāĻžāĨ¤
5. Final Diagnosis for Prescription Note
Dx: Low Back Pain (LBP), Etiology Undetermined; Suspected Mechanical LBP Âą Lumbar Muscle Spasm.
6. Specialist Referral
Orthopedics / Physical Medicine & Rehabilitation Specialist.
7. Overall Diagnostic Confidence
0.78/1.00 â Moderate-to-High Confidence for Symptom-Level Working Assessment.
āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ structural āĻŦāĻž metabolic disease-āĻāϰ āĻāύā§āϝ āĻĒāϰā§āϝāĻžāĻĒā§āϤ evidence āύā§āĻāĨ¤
Author Name: Md.Rafiqul Islam Lipu
Publication Date: Wednesday, 21 October 2026
Time: 05:16 PM (Bangladesh Standard Time, UTC+06:00)
Department: Orthopedics
Proposed TC Number: 1419
Proposed Department Case Number: 185
LIPU MED â Evidence-Based Clinical Prescription Review
Disclaimer: āĻāĻ āύāĻŋāĻŦāύā§āϧāĻāĻŋ prescription-based retrospective educational assessmentāĨ¤ āϰā§āĻā§āϰ āϏāĻŽā§āĻĒā§āϰā§āĻŖ āĻāϤāĻŋāĻšāĻžāϏ, āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž āĻ āĻĒā§āϰāϝāĻŧā§āĻāύā§āϝāĻŧ investigation āĻāĻžāĻĄāĻŧāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āϰā§āĻāύāĻŋāϰā§āĻŖāϝāĻŧ āĻŦāĻž āĻŦā§āϝāĻā§āϤāĻŋāĻāϤ āĻāώā§āϧā§āϰ regimen āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤